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ABSTRACT 
Surface-Enhanced Raman Scattering (SERS) has the potential to be a rapid 
disease diagnostic platform. SERS is a well-known ultrasensitive, label-free method for 
the detection and identification of molecules at low concentrations. The Raman cross-
sections are primarily enhanced by plasmonic effects for molecules close to (< 5 nm) the 
surface of nanostructured metal substrates. Due to the unique Raman vibration features 
that provide molecular signatures, we have shown that SERS can provide a rapid (< one 
hour), label-free, sensitive and specific diagnosis for a number of diseases. This work 
demonstrates the capability of SERS to be an effective optical diagnostic approach, in 
particular, for bacterial infectious diseases such as urinary tract infections (UTI) and 
sexually transmitted diseases (STD), and cancer cell identification. More specifically, this 
work demonstrates the ability of SERS to distinguish different vegetative bacterial cells 
with species and strain specificity based on their intrinsic SERS molecular signatures. 
With the exception of C. trachomatis - the causative agent of chlamydia - whose SERS 
molecular signatures are found to be aggregated proteins on the cell membrane, all 
bacterial SERS molecular signatures are due to purine molecules resulting from nucleic 
acid metabolism as part of the rapid onset of the starvation response of these pathogens. 
 vii 
The differences in relative contribution of different purine metabolites for each bacterium 
gives rise to the SERS strain and species specificity. The ability of SERS to distinguish 
cancer and normal cells grown in vitro based on changes of SERS spectral feature as a 
function of time after sample processing is also demonstrated. Furthermore, the 
difference of spectral features on the gold and silver SERS substrate of the same bacteria 
can be used as additional attribute for identification. This work demonstrate the potential 
of SERS platform to provide antibiotic-specific diagnostics in clinical settings within one 
hour when combined with a portable Raman microscopy instrument, an effective 
enrichment procedure, multivariate data analysis and an expendable SERS reference 
library with drug-susceptibility profile for each bacterial strain determined a priori, as 
well as the ability of SERS platform as a powerful bioanalytical probe for learning about 
near cell membrane biochemical processes.  
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1. Introduction 
Surface Enhanced Raman Scattering (SERS) arises from the resonant excitation 
of localized surface plasmons which enhance the local fields close to (< 5 nm) the surface 
of nanostructured metal surfaces. Raman scattering enhancements, typically of the order1 
of ~104 – 108  provided by surface plasmon resonance effects allow SERS to be a 
sensitive molecular spectroscopy for detection and identification of molecules at low 
concentrations (~ µM range) without the need of fluorescent labeling at least for 
molecules that are very near the metal surface. The electromagnetic and the chemical 
mechanisms that account for the SERS enhancement, which lead to the advantages of 
SERS as label-free, easy-to-use, sensitive and specific optical biosensor for biomedical 
applications, are summarized in this introductory chapter.  
 
1.1 – Theory of Surface Enhanced Raman Scattering (SERS) 
SERS was discovered, though not recognized at that time, by Fleischmann et al.2 
in 1974 who observed intense Raman scattering from pyridine adsorbed onto a roughened 
silver electrode surface, which couldn’t be explained simply by an increased molecular 
concentration on the roughened electrode. Since then SERS effect has been observed for 
many molecules adsorbed onto the surface of metals with a variety of morphologies and 
local chemical environments. Silver, gold and copper3 are the common choices of metal 
for SERS substrate. These metals contain lots of free electrons and we will see 
mathematically how this property lead to large enhancement of the Raman Scattering 
signal.  The large electric field enhancement results from metal surfaces that are 
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roughened on the nanoscale, which could be single or aggregated colloidal metal particles, 
etched metal surface, metallic nanoparticles deposited onto glass surface by evaporation 
or sputtering and arrays of nanoparticles created by lithographic techniques as examples.3  
SERS differs from normal Raman spectroscopy in several ways. For examples, 
there are no strong correlation between the Raman and the SERS spectrum of the same 
molecule as the Raman selection rule do not fully apply to SERS. It’s not uncommon to 
observe forbidden Raman modes in the SERS spectrum.  The intensity of bands observed 
falls off with increasing frequency, for example C-H stretches tend to be relatively weak 
in SERS.3 In addition, fluorescent background which is problematic especially in Raman 
spectrum of hydrocarbon molecules is effectively quenched by energy transfer to the 
metal surface.  
The signal enhancement mechanism of SERS was proposed independently by two 
groups of researchers Van Duyne et al.4 and Creighton et al.5. Van Duyne et al. proposed 
an electric field enhancement of the Raman Scattering for molecules in close proximity to 
the metal surface due to the presence of localized surface plasmon resonances, while 
Creighton et al. believed the broadening of the electronic state of the molecule due to the 
interaction with the metal surface resulted in the large Raman scattering cross-sections. 
As will be shown, both theories are correct conceptually but not in detail. 
 3 
1.1.1 - The Electromagnetic Enhancement Mechanism of SERS 
 
Figure 1-1  Schematic representation of plasmonic oscillation (re-created based on6) 
 
In this theory the electric field of the incident and the scattered light are enhanced 
by the electromagnetic field from the plasmonic resonance.7 A plasmon is the collective 
oscillation of the electron cloud of a metal when excited by an incident electromagnetic 
wave. The excitation of the resonant oscillation of conduction electrons at the interface of 
the nanostructured metal surface is called a surface plasmon. This excitation can be 
propagating, such as on the surface of a grating, or can be localized, such as on the 
surface of a spherical metal nanoparticle. For a simple description of SERS, we will focus 
on the latter case. If the incident direction of propagation of the electromagnetic wave 
relative to the spherical nanoparticle is along the z-axis, as shown in Figure 1-1, then the 
electric field outside of the sphere Eout can be expressed as,  𝐸"#$ = 𝐸&𝑧 − 𝛼𝐸&[ ,⃑-. − /,-0 (𝑧𝑧 + 𝑥?⃑? + 𝑦?⃑?)]                                                      Equation 1  
The first term is the electric field of the incident electromagnetic wave, and the second 
term is the dipole moment induced by the polarization of the electron cloud of the metal 
sphere. r is the radial distance and  𝑧𝑧, 𝑥?⃑?, 𝑦?⃑? are the Cartesian coordinates of the induced 
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dipole which can be neglected at a distance very close to the surface of the sphere. The 
polarizability of the electron cloud of the metal α is described as,  𝛼 = 𝑔𝑎/ and 𝑔 = :;<:=:;>?:=                                                                                      Equation 2 
where a is the radius of the metal sphere, ε0 is the dielectric constant of the medium 
around the metal particle, and εi is the dielectric constant of the metal.  
 The displacement of the electron cloud from its equilibrium position is maximized 
when the frequency of the incident electromagnetic wave matches the intrinsic frequency 
of the collective plasmon oscillation, i.e. at the plasmonic resonant frequency. Excitation 
at near the plasmonic resonance wavelength greatly increases the local field experienced 
by a molecule adsorbed onto the metal surface. Mathematically, plasmonic resonance 
occurs when 𝑅𝑒(𝜀C) = −2𝜀&, which means Eout will be very large if α is large. This is the 
reason metals such as gold and silver are able to provide good enhancement to Raman 
Scattering with visible/near-infrared excitation, because they have free electrons that 
make the real part of εi a large negative value and the imaginary part to be very small.  
The value of the real part of εi will dictate the resonance frequency, while the imaginary 
part will apply to the loss of the resonance. As shown in Equation 2, the plasmonic 
resonance condition depends on the dielectric constant of the surround medium ε0, 
therefore the plasmonic condition of a metal nanoparticle can be modified by changing 
the dielectric of the external environment, e.g. addition of salt.  
It’s clear from Equation 1 that the electric field strength falls off with radial 
distance r from the metal surface as 𝐸"#$ ∝ 	 G-. . The SERS intensity depends on the 
 5 
absolute square of Eout2 evaluated on the surface of the sphere (r = a). From Equation 1, 
this is given as, 𝐸"#$? = 𝐸&?[|1 − 𝑔|? + 3 cos? 𝜃(2𝑅𝑒(𝑔) + |𝑔|?)]                                             Equation 3 
θ is the angle between the incident field direction and the location r on the sphere surface.  
At resonance when |𝑔| is large, Equation 3 can be simplified as 𝐸"#$? = 𝐸&?|𝑔|?(1 +3 cos? 𝜃). This means the field intensity is largest when the angle θ is either 0° or 180°, 
i.e. along the polarization direction. The ratio between the largest and smallest field 
enhancement as a function of θ is 4.  
It’s important to note that the surface plasmon will not only excite the incident but 
also the scattered field. A physical way to look at the field enhancement by plasmonic 
resonance is the metal particle acts as an antenna that amplifies both the incident and the 
scattered light. Therefore the overall electric field enhancement will need to consider 
both the incident and the scattered field enhancements,  𝐺P = QRSTU QRSTVUQ=W = 16|𝑔|?|𝑔Y|?                                                                              Equation 4 
where the primed symbols refer to fields for the scattered light. For Stokes shifts at lower 
frequency, |𝑔|? and |𝑔Y|? is maximized at approximately the same wavelength, then the 
enhancement will be about g4.4 This may also help to explain why SERS intensity 
typically fall off for highest frequency modes. At higher frequency the plasmonic 
resonance can excite either the incident or the scattered field but not both, resulting at 
lower overall SERS enhancement. 3   
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1.1.2 - The chemical enhancement mechanism of SERS 
 
Figure 1-2  The energy level diagram for a model adsorbed on a metal surface. The HOMO and 
LUMO molecular orbitals of the molecule are broadened by their interaction with the metal states. 
The charge-transfer excitation is indicated by the arrow. 3 
 The primary evidence suggesting the presence of a second SERS enhancement 
mechanism independent of the electromagnetic enhancement comes from the observation 
that nitrogen-containing molecules have stronger SERS intensities than other molecules 
under the same experimental condition. This observation is difficult to explain by the 
electromagnetic enhancement mechanism alone because this mechanism should be 
chemically nonselective. A second line of evidence supporting a second enhancement 
mechanism comes from the electric potential-dependence of Raman intensity as observed 
in Fleischmann’s experiment.2 The chemical enhancement mechanism suggested by 
Creighton et al. 5 offers an explanation for this chemical selectivity of SERS. In this 
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mechanism, the electronic states of the adsorbed molecule are broadened due to 
interaction with the metal surface and new electronic states can also be created by 
combining with the metal states (“charge-transfer”), causing a shift of the electronic 
transitions of the molecule  (usually from UV visible region).  Both processes are 
illustrated in Figure 1-2. As discussed above, both the electromagnetic and chemical 
mechanism offer partial explanation but neither theory offers a complete picture of SERS.  
  
1.2 – The Advantages of SERS 
It’s easy to see from Equation 4 why SERS is a sensitive method: a modest 
increase in the local electric field of 10 – 100 produces an overall Raman enhancement 
that scales as E4 or approximately a 104 – 108 amplification at the surface plasmon 
frequency. When SERS is coupled with the electronic resonance effect the combined 
enhancement can allow detection of a single molecule. 8  Additionally, the narrow Raman 
scattering spectral features make possible for precise determination of a molecular 
identity because vibrational motions are intrinsic markers of the molecule itself. Different 
molecules in a mixture can be simultaneously detected and identified because each 
molecule has unique narrow spectral signatures. As seen in later discussions, this 
multiplexing capability will allow us to accurately determine the composition and relative 
concentration of each component in complex biological samples to be determined. Since 
the localized plasmonic enhancement requires molecules to be at close proximity to the 
nanostructured metal surface, SERS is a useful tool for studying biochemical processes 
occurring at near-cell-membrane extracellular region as well as cell membrane 
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components when living cells are placed on a nanoparticle substrate. Potential 
interferences from water at near-infrared excitation frequencies have minimal impact on 
the SERS spectrum because water has a weak inherent Raman scattering cross-section.  
This is a particular beneficial property for studying biological systems especially relative 
to IR vibrational techniques. Since Raman depends on the inherent vibrational motions of 
samples for identifying characteristic signal, , no extrinsic labeling as often employed in 
fluorescence studies of biological systems is required. Furthermore, the fluorescent 
background which can sometimes be problematic in Raman spectroscopy, particularly for 
biological systems, is minimized as mentioned above by energy transfer to the metal 
surface.  
In the next few chapters, the advantages of SERS as label-free, easy-to-use, rapid, 
sensitive and specific disease diagnostic platform with multiplexing capability are 
demonstrated. Specifically, the potential of SERS platforms is demonstrated for urinary 
tract infection, sexually transmitted diseases and cancer diagnostic are discussed. These 
diseases are chosen for SERS study because they are some of the most common health 
concerns worldwide and result in billions of dollars in healthcare costs. It is shown that 
the SERS platform can find molecular biomarkers that identify the causative agents of 
bacterial infectious diseases and distinguish normal and tumorigenic cells which are 
grown in laboratory environment. At the same time we will also use SERS to study the 
biochemical process that lead to the observation of these biomarkers on the SERS 
spectrum. These proof-of-concept experiments show the ability of SERS as a novel 
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biosensor for these diseases as well as a powerful bioanalytical probe for studying 
extracellular metabolomics.  
 
2. SERS Diagnostic Platform: Urinary Tract Infections 
2.1 - Prevalence and Significance of Urinary Tract Infections 
Urinary tract infection (UTI) is one of the most common types of bacterial 
infection in human evident by the appearance of large amounts (≥ 105 cfu/mL, colony 
forming unit) of bacteria in mid-stream urine.9 UTI is among the leading reasons for 
primary care medicine treatments. 10, 11 Approximately 50% of all women will have UTI 
at least once in their lifetime, about 20% will have a recurrent UTI and large portion of 
this group will turn into chronic UTI. 11,12 UTIs pose a heavy burden to the health care 
system. In the US alone, UTIs are responsible for more than 7 million doctor’s office 
visits and over one million hospital admissions, at a cost of ~$1 billion per year. 13,14,15  
UTI is also one of the most common hospital-acquired infections, responsible for up to 
35% of nosocomial infections.16 
Among the causative bacterial strains for UTI, Escherichia. coli is the 
predominant bacterial species accounting for up to 70% of UTI clinical presentations.10  
Other common UTI pathogens include Staphylococcus saprophyticus (5-10%), Klebsiella 
pneumoniae (4-7%), Proteus mirabilis (4-5%), Pseudomonas aeruginosa, and 
Enterococcus faecalis.10,16,17  A mid-stream bacterial count of 105 cfu/mL (colonies 
forming unit/mL) in free collection urine is used as indication of UTI in symptomatic 
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patients and the recommended level for antibiotic treatment.9 Amid the growing concern 
of antimicrobial resistance, more drug-resistant bacterial strain are associated with UTI 
cases, such as the discovery of fluoroquinolone-resistant E. coli strains, extended 
spectrum beta lactamase (ESBL) E.coli, K. pneumoniae, and other Gram-negative strains 
as well as the increasing resistance to the combined trimethoprim/sulfamethoxazole 
antibiotic by many UTI strains.18,19,20 The number of antibiotics available for successful 
treatment has been significantly reduced due to these growing trends of drug-resistance.  
 
2.2 - Overview of Current UTI Diagnostic Methods 
The current UTI diagnostic method can be summarized into two categories: 
nonculture and culture methods.  Examples of non-culture methods are urine microscopy, 
the nitrite test and the leukocyte esterase test.21 In the urine microscopy method bacteria 
cells are counted after being fixed with Gram stain in the patient’s urine sample. The 
presence of bacteria in urine can also be detected indirectly by the amount of leukocyte 
cells in the urine sample which will increase dramatically in immune-response to an UTI 
episode.22 Both tests are simple and the cost per test is low.  However both tests are 
insensitive to low bacteria concentration (≤ 105 cfu/mL), and a first-void urine sample 
with two hours incubation time in the lab is required for both tests to work properly.23  
Alternatively bacteriuria can be detected through a nitrite test that measures the chemical 
conversion of nitrite to nitrate by bacterial activity in the urine sample. The nitrite test is 
the basis for commercially available dip-strip test. The nitrite test is susceptible for 
members of the Enterobacteriaceae family,22 but its usefulness is limited because nitrite 
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production is not associated with other common UTI-causing pathogens such as the S. 
saprophyticus and the Pseudomonas species.24 Moreover first-void urine and ~4 hours 
incubation time is necessary for bacterial conversion of nitrate to nitrite to reach 
sufficient level for detection.22 The leukocyte esterase test utilizes the hydrolysis of ester 
substrate by esterase released by neutrophils.25 The esterase test detects esterase from 
both the intact and lysed leukocytes, but the test can yield false positive results when the 
urine is contaminated with bacteria from the vaginal fluid which naturally contain 
esterase or containing eosinophils or the Trichomonas species.22 These non-culture tests 
are simple, inexpensive and easy-to-use, but they detect the presence of bacteria through 
indirect measurement and thus provide no information about the species or strain identity, 
essential for establishing the antibiotic susceptibility profile required for drug prescription, 
or the quantity of the causative pathogen which can help monitor drug efficacy and 
disease progression.  
The advances of genotyping-based techniques such as nucleic acid amplification 
tests (NAAT) allow more rapid molecular-based approaches and offer the advantage of 
high sensitivity and specificity compare to other non-culture detection methods. However, 
the high sensitivity and specificity of NAAT could mean false positive due contamination 
by exogenous sources of DNA.26,27 The need for matching genetic primers and the 
requirement of a laboratory setting can be problematic for NAAT as point-of-care 
diagnostic method.28,29 
Bacteria culturing, on the other hand, is the current gold standard method for UTI 
diagnosis. It remains the only method that provides information about bacterial strain 
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identity, quantity and antibiotic susceptibility simultaneously in patient urine sample.22  
However this method typically required 24-48 hours incubation time for bacterial growth, 
and even longer incubation required for antibiotic susceptibility determination. The long 
incubation time is the major drawback especially when recurrent or chronic infections are 
suspected and multiple urine samples from the patient are needed for definitive 
diagnosis.30 As a result of this long waiting period, physicians are often resort to 
prescribing broad spectrum antibiotics based on patient symptoms, which has 
significantly contributed to infective treatment, increased care cost and the rising 
occurrence of multi-drug resistant bacterial strains.18 Therefore, a rapid diagnostic 
method that provides microbial identification and drug susceptibility within the time 
frame of a patient presenting at a clinic (<1 hour) is urgently needed to allow appropriate 
use of narrow spectrum antibiotics. Rapid diagnostics is also cited as a critical need to aid 
the clinical development of new antibacterial drugs.31  
 
2.3 - Introduction of SERS-based UTI Diagnostic Platform 
SERS is an attractive candidate for bacterial diagnostics because it is a rapid, ease-
to-use, information-rich method that does not require additional labeling procedures for 
identification purposes. SERS arises from the well-known Raman cross-section 
enhancement effect on molecules close to (< 5 nm) the surfaces of nanostructured metal 
substrates. Since Raman vibrational features are uniquely dependent on molecular 
structure, precise determination of the molecular identity from a SERS spectrum is 
possible. It’s also possible to identify different molecular components in a mixture in a 
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single spectrum based on the unique narrow vibrational signatures of each component, 
which is essential for analyzing biological mixture.   
SERS spectra of laboratory-cultured bacterial cells have been reported over the 
past fifteen years.32,33,34,35,36 The use of SERS as a novel approach to rapid, growth free 
UTI diagnostics has been proposed in several previous studies.37,38,39,40,41,42 In these 
studies clinical isolates or bacterial species known to cause UTI are cultured in standard 
growth media and SERS signatures are obtained.  In a previous study it was shown that a 
group of six E. coli clinical isolates grown in bacterial growth media can be distinguished 
by their SERS spectra when combined with multivariate classification algorithm.38 This 
study also demonstrated that the potential of SERS to provide strain specificity. In nearly 
all of these bacterial SERS studies, the major vibrational bands of the observed bacterial 
spectra are attributed to components of the outer bacterial cell wall structures, such as 
peptidoglycan, lipids, lipopolysaccharides or membrane proteins and nucleic acids.  
Our efforts in the laboratory have been resulted in development of a SERS-based 
UTI diagnostic platform with the advantages of speed and ease-of-use with the potential 
to be a point-of-care diagnostic device. A crucial component of the SERS UTI diagnostic 
platform is a gold nanoparticle covered silica substrate which results from a metal ion 
doped sol-gel procedure which are used here for the acquisition of highly sensitive and 
robust SERS spectra of vegetative bacterial cells with 785 nm excitation.34 After the 
acquisition of the bacteria SERS spectra a multivariate analysis “barcode” procedure 
based on the sign of the spectral second derivative as a function of the scattered 
wavelength are applied to allow rapid determination of the bacterial strain identity.43 
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Furthermore, in contrast to the usually reported molecular origin of these SERS spectra 
being attributable to cell wall structures, we have shown that the dominant molecular 
species contributing to the 785 nm excited SERS spectra of bacteria are the metabolites 
of purine degradation: adenine, hypoxanthine, xanthine, guanine, uric acid and AMP44. 
These molecules result from the starvation response of the bacterial cells in pure water 
washes following enrichment from nutrient rich environments.  
  In contrast to previous SERS UTI studies described above, our primary objective 
is to determine if high quality SERS spectra can be obtained from UTI causative bacteria 
grown in human urine and to demonstrate these obtained SERS spectra can provide 
growth-free species and strain specificity when combine with multivariate classification 
algorithms. We show that our SERS-based UTI diagnostic platform can identify the 
bacterial strain grown in the urine sample at clinically relevant concentration (105 cfu/mL) 
in less than a one hour time frame.  Twelve UTI clinical isolates with previously 
determined antibiotic susceptibilities are used in this study, hence successful SERS-based 
classification will also provide growth-free determination of antibiotic susceptibility or 
resistance for this set of organisms. In addition, a prototype procedure for bacterial 
enrichment from urine is developed as part of the SERS UTI diagnostic platform. The 
molecular origins of the bacterial SERS signature will be discussed as well. The success 
of the rapid SERS UTI diagnostic platform will make possible the administration of 
appropriate narrow spectrum antibiotics, earlier initiation of appropriate therapy and 
better real time monitor of treatment efficacy for patients with UTIs.   
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2.4 - Methods and Materials 
Bacterial samples and preparation.  The twelve bacterial strains used in this study (see  
 and Table S-7-2) were donated by BD® Life Sciences and were all isolated from clinical 
urine specimens. Their antimicrobial susceptibility profiles were determined by the BD 
Phoenix™ Automated Microbiology System45 prior to these SERS investigations and are 
summarized for a range of antibiotics (See Table S-7-1 and Table S-7-2).  These samples 
include strains of two Gram-negative bacteria, Escherichia coli (6 strains) and Klebsiella 
pneumoniae (2 strains), and two Gram-positive bacterial species, Staphylococcus 
saprophyticus (2 strains) and Enterococcus faecalis (2 strains).  
All twelve bacterial strains were grown in freshly collected human urine that had 
been previously processed to remove solid materials. To prepare the processed urine, first 
or second urine of the day from anonymous healthy donor was collected (100 mL) into 
two 50-ml sterile centrifuge tubes and centrifuged at 10,000 rpm (Eppendorf® 5805) for 
20 minutes at (18 °C).  After centrifugation, the pellet at the bottom is discarded and the 
supernatant urine is transferred to sterile containers. The optical density (OD600nm) of the 
supernatant urine is recorded and is used to compare with the OD after spiking with 
bacteria to verify the urine collected is initially free of bacterial cells.  Then 10 mL of the 
supernatant urine are transferred from the container to a sterile test tube. Approximately 
three loops (~ 30 µL) of overnight bacterial culture grown in tryptic soy broth (BD®) are 
inoculated into this urine supernatant and allowed to grow to OD of 0.1. The bacterial 
concentration at this OD is determined by serial dilution to ~107 cfu/mL (See Appendix 
8.2). 0.5 mL of this ~107 cfu/mL urine culture are spiked into about 50 mL of the 
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remaining urine supernatant and incubated for 30 minutes at room temperature.  
To isolate the bacterial cells from the spiked urine sample, the urine sample is 
centrifuged at 10,000 rpm for 20 min and the resulting bacterial pellet is quantitatively 
transferred to a 2 mL micro-centrifuge tube. The bacterial pellet is then washed with 0.5 
mL of ice-cold distilled water four times and centrifuged for 1 minute at 10,000 rpm 
between each washing cycle. Washing in ice-cold water will ensure consistent 
synchronization of bacterial stress response for each experiment. This centrifuging-
washing procedure will result in a final enriched concentration of ~108 cfu/mL in a 
volume of ~50 µl. For the subsequent SERS spectra acquisition, 1 µL of the enriched 
sample is pipetted onto the SERS active substrate and allowed to air-dry for about 5 
minutes. This procedure was repeated for all twelve bacterial strains. The total time for 
sample enrichment to placement on the SERS substrate for Raman acquisition was ~40 
min.   
 
Figure 2-1 The overall workflow of the SERS UTI diagnostic platform for recovering E. coli 
BD6594 cells grown in spiked, unprocessed urine from anonymous healthy donor.  
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In another set of SERS measurements, bacterial cells from one of the twelve UTI 
bacterial strains, E.coli BD6594, were spiked into non-processed, i.e. non-centrifuged 
urine which thus contain natural sedimentary materials. The amount of the natural 
sedimentary material, which consists of whole cells and cell debris from the lining of the 
urinary tract and inorganic crystals,46 is approximately 1-2 mL in 50 mL urine from 
anonymous healthy donor and may be more in real UTI patient samples due to presence 
of white blood cells.22 Therefore, the centrifugation method mentioned above alone will 
not be sufficient to consistently recover all bacterial cells from the urine sample. Hence 
for this proof-of-concept experiment a differential filtration scheme was developed to 
remove these sedimentary materials while retaining the bacterial cells, as shown in Figure 
2-1. About 10 mL of the urine from anonymous healthy donor is inoculated using 
overnight E.coli BD6594 bacterial culture in tryptic soy broth and allow to grow to an 
OD of 0.1. Then 0.5 mL of the inoculated urine is spiked into 50 mL non-processed urine 
from the same donor to bring to concentration of bacterial to 105cfu/ml. Meanwhile, a 
four-stage gravitational filtration system with decreasing pore size is assembled as shown 
in the figure. The filters used in the system are 30, 10 and 5 micron Nylon mesh filter 
(Cole-Palmer®). Three sterile 50 mL conical centrifuge tubes are obtained and their 
bottoms are cut off. The mesh filter are capped at the bottom of the conical centrifuge 
tube and secured by tape and parafilm to prevent leaking. Then the three centrifuged 
tubes are stacked on top of each other in the order of decreasing pore size. In addition, 
~200 mg of glass wool is added to the bottom of the first tube to complete the four-stage 
filtration system. To use the four-stage filtration system to recover the bacterial cells, the 
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50 mL bacteria spiked urine sample is slowly pour into the system and the filtered urine 
is collected after the 5 micron mesh into a sterile 50 mL centrifuge tube. The subsequent 
steps of the bacterial enrichment procedure are identical to that for the processed urine 
samples described above. The total preparation time using this procedure is still around 
~40 minutes since the filtration step takes ~1-2 minutes. This procedure was not carried 
out for all twelve bacterial strains because a new four-stage filtration system needs to be 
re-constructed for each new sample. However an analogous re-usable 
filtration/centrifugation scheme like this can be developed for a SERS UTI diagnostic 
system for real-world clinical samples. This prototype apparatus is intended to 
demonstrate how bacterial cells can be enriched and recovered from un-processed urine 
for successful acquisition of SERS spectra at clinically relevant concentrations as shown 
below.  
SERS active substrate All SERS spectra are obtained using an in-situ grown, 
aggregated gold nanoparticle covered SiO2 substrate developed in our laboratory.34 
Characterization and performance of these SERS active substrate have been previously 
described and characterized.34, 43, 44,47,48,49,50 These substrates are produced by a two-stage 
reduction by sodium borohydride of an Au3+ ion doped sol-gel that results in small (1-10 
particles) aggregates of ~80 nm diameter gold nanoparticle covered SiO2 substrate.  
Figure 2-2 shows the SEM image of the gold SERS active substrate. Ag+ doped sol-gels 
can also be prepared by this methodology. 
SERS spectra acquisition Bacterial SERS spectra are acquired by an RM-2000 
Renishaw® Raman microscope employing a 50x (infinity-corrected, 0.75 numerical 
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aperture) objective and 785 nm excitation. Incident laser powers of ~ 0.45 mw and ~10 
seconds of illumination time are typically used to obtain the reported bacterial SERS 
spectra.  The illuminated Raman excitation field of view is ~30 µm x 2.5 µm. The 520 
cm-1 band of a silicon wafer is used for frequency calibration. Typically ten spectra per 
sample range from 200-1800 cm-1 were obtained for each experimentally reported 
bacterial spectrum. The peak frequency precision is ± 0.5 cm-1. Spectral acquisition took 
less than 10 min. The acquired SERS spectra are averaged and baseline-corrected with 
GRAMS® (Thermo®). The SERS spectra are normalized and plotted by MATLAB® 
(r2013b) and the spectra are displayed vertically offset for clarity.  
 
Figure 2-2 Scanning electron microscopy (SEM) image of the gold SERS active substrate 
showing the gold nanoparticle aggregate covering the surface of the substrate.  
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Data analysis  Classification by multivariate machine-learning algorithm is an 
important component of our SERS UTI diagnostic platform. Machine-learning algorithm 
allow rapid processing and information gathering from large amount of spectral data and 
can be used to identify unknown spectra based libraries built from previously collected 
data. In this analysis, a partial least square – discriminant analysis (PLS-DA) algorithm 
was used to achieve bacterial strain identification based on SERS spectra. The PLS-DA 
algorithm is part of the PLS toolbox (v7.3.1) developed by Eigenvector Research, Inc. 
(Seattle, WA) based on MATLAB® (r2013b) platform. A polynomial fitting function in 
MATLAB® was employed to remove broad variable baseline features from individual 
SERS spectrum. A previously developed barcode methodology43 based on the sign of the 
second derivative of the baselined SERS spectra as a function of scattered wavelength 
converts all baselined spectra into a barcode, a series of “1”’s or “0”’’s, which are the 
input vectors to the PLS toolbox. This combination of barcode and multivariate 
classification algorithm results in greater sensitivity and specificity for this SERS-based 
spectral classification technique.    
 
2.5 - Results and Discussion  
SERS spectra of bacterial strains grown in filtered urine  
SERS spectra of twelve bacterial clinical isolates grown in filtered urine and 
diluted with urine to 105 cfu/mL are shown in Figure 2-3. The shaded area indicates ± 
one standard deviation of the averaged intensity of each spectrum. Six strains of E.coli, 
and two strains each of S. saprophyticus, K. pneumoniae and E. faecalis are shown in this 
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figure and color coded by species. Each spectrum is an average of ~10 individual SERS 
spectra acquired on our gold SERS active substrate. All spectra exhibit excellent S/N as 
seen on this figure. As already indicated, the total time for acquisition of the SERS 
spectra of bacteria from spiked processed urine sample is ~40 minutes, and the bulk of 
this time is spent on the sample enrichment and centrifugation steps in this bench-top 
prototype procedure. Figure 2-3 demonstrates the ability of our SERS UTI diagnostic 
platform to obtain high quality SERS spectra from enriched bacteria sample which are 
grown in spiked urine within one hour time-frame. Furthermore, this figure shows that 
our SERS platform has the ability to report UTI cases with bacterial concentration below 
105 cfu/mL which is the current clinical definition.  
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Figure 2-3 SERS spectra of twelve UTI clinical isolate grown in processed urine.  The shaded 
area indicates the standard deviation for each spectrum.  
 As seen in Figure 2-3, with the exception of the two S. saprophyticus strains, the 
differences between the SERS spectra of the E.coli, K. pneumonia and E. faecalis strains 
are greater than the difference between the strains of a given species. A number of 
vibrational bands are common among these bacterial spectra, such as the strong band in 
the 725-735 cm-1 region in all spectra as well as the 660 cm-1, 960 cm-1, 1240 cm-1, 
1315cm-1, and 1450 cm-1 bands. The molecules contributing to these vibrational bands 
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will be discussed shortly. Comparing Figure 2-3 with the drug susceptibility profile in 
Table 4-1 and in Table S-7-2 shows that there are no clear correlation between the SERS 
spectra similarity and the drug susceptibility profile. However, a larger dataset is needed 
to definitively determine the relationship between SERS spectral similarity and the drug 
susceptibility.  
Molecular origin of SERS signal and species/strain specificity  
In our previous reports of SERS spectra of vegetative bacterial cells44, 48, 49, 50 we 
found that virtually all observed vibrational features could be assigned to the spectral 
contributions of six purines molecules: adenine, hypoxanthine, xanthine, guanine, uric 
acid and AMP. The presences of these molecular species in our bacterial SERS spectra 
are attributed to the nucleotide metabolic degradation pathway due to the rapid onset of 
the bacterial starvation response. These molecules are secreted by the bacterial cells to 
the extracellular regions near the outer cell membrane in rapid response to being in a 
nutrient-depleted environment. The identity of these molecular components have been 
determined by isotopic labeling, model compound studies, bacterial supernatant studies, 
gene knockout studies, enzyme reactant effects and mass spectrometry.44,51 In the UTI 
bacterial SERS spectra we also found that nearly all the vibrational bands can be assigned 
to these six molecules with the addition of another purine molecular component, 
guanosine, identified here. Each of the bacterial strain spectra in Figure 2-3 is best-fit by 
a linear combination of these seven purine components and is shown in Figure 2-4 and 
Figure 2-5. The linear coefficient of the best-fit for each strain is given in Table S-7-5. 
The normalized SERS spectra of the seven purine compounds are shown in Figure S-7-6 
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and are used for this best-fitting procedure. Nearly all vibrational features in the bacteria 
spectra are captured in the calculated, best-fit spectra. Each bacterial spectrum has 
different amount of these purine components and the different relative contributions of 
each purine molecule is the intrinsic biomarker for the identification of the bacteria via 
this SERS diagnostic platform. To visualize the relative contributions of these seven 
purine molecular components to each bacterial spectrum, a bar graph showing these best-
fit determined relative amounts (in Table S-7-5) is shown in Figure 2-6. This figure 
shows that each species has a different reproducible mixture of purine molecules 
contributing to its spectrum. For example, adenine and guanosine are the largest and 
second largest contributors respectively to the E. faecalis spectra, but for E. coli the two 
largest molecular components are hypoxanthine and xanthine. This difference in main 
purine contributors between these two species give rise to the species specificity observed 
with SERS. Furthermore, strains of a given species have similar composition of these 
seven purines, but the amount of each purine is not identical. For example, E.coli 
BD6594 spectrum has more hypoxanthine contribution than xanthine contribution, while 
for the E.coli BD6880 spectrum xanthine contributes more than hypoxanthine. The 
differing amount of these purine components within the same species give rise to the 
strain as well as species specificity of SERS, as well as a basis for the successful 
classification and diagnostic capability  by multivariate analysis methods.   
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Figure 2-4 best fits (red) resulting from a linear combination of various amounts of the seven 
purine molecule SERS spectra to the observed (blue) SERS spectra of the six E.coli bacterial strains.  
 
 26 
 
Figure 2-5  best fits (red) resulting from a linear combination of various amounts of the seven 
purine molecule SERS spectra to the observed (blue) SERS spectra of each of S. saprophyticus, E. 
faecalis and K. pneumoniae strains. 
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Figure 2-6 the relative contribution of each of the seven purine molecules to each bacterial 
spectrum is summarized in this bar graph. The numerical value is shown in Table S-7-4 PLS-
DA classification sensitivity and specificity for twelve UTI bacteria SERS spectra. 
 
 
 
 
2.6 – Introduction to linear regression machine-learning methods for 
strain identification from SERS spectra of an unknown sample  
A partial least square (PLS) statistical method (Eigenvector Research Inc., Seattle, 
MA) was used to construct a predictive model based on the SERS spectra of the twelve 
UTI bacterial strains. A set of SERS spectra for a bacterial strain of an unknown identity 
grown in unprocessed urine (i.e. not centrifuged prior to spiking with bacterial cells) was  
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used  to test the predictive model to see if the model can correctly identify the strain and 
hence offer antibiotic-specific diagnostic capability.  
Introduction to Linear Regression  
Scientific research often involves using controllable and/or easy-to-measure 
variables (factors) to explain or predict the behavior of other variables (response). If there 
are only few factors which are not significantly redundant (collinear) and a well-
understood relationship exists between the factors and the response, a linear regression 
can be a good way to gather as much information from the dataset of interest as possible. 
Most of the time the primary objective for a researcher is merely identifying the most 
important factors and use them to construct a good predictive models. For example, the 
multiplexing capability of SERS allows the estimation of the amount of different 
chemical components in a UTI bacterial spectrum as shown in Figure 2-6. In this case the 
factors are the data-points that comprise the SERS spectrum; they are numbered in the 
thousands but are highly collinear. The response are the chemical components 
contributing to the SERS spectra of a particular UTI bacterial strain that we want to know 
and use as unique signature to indicate the presence of this strain in future samples.52   
Partial least squares (PLS) is a method for constructing predictive models when the 
factors are many but highly collinear. PLS was developed in the 1960’s by Herman Wold 
as an econometric techniques, but quickly found use in chemical engineers and 
chemometricians. In principle, linear regression can be used when the number of factors 
is very large. However, not every one of these factors are needed to construct a good 
predictive model; there are only few important underlying factors that account for most 
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of the variation in a set of SERS spectra. The goal of PLS is to try to extract these few 
important underlying factors, or so-called latent variables (LV) that account for as much 
variation in the spectral dataset as possible. In this sense PLS bears some resemblance to 
principle component analysis (PCA) since both methods aim to find the important 
variables to describe the spectral dataset.  
How does PLS works 
Figure 2-7 Schematic Outline of PLS method.52 
Figure 2-7 shows a schematic outline of the 
PLS method. In this application, the sample will be 
the SERS spectra of each of the twelve UTI 
bacterial strains and the population will be the 
SERS spectra acquired from an unknown urine 
sample. The overall goal (shown in the lower box) 
is to build a model that uses the most important 
factors (latent variables) gathered from the samples 
to predict the response when applying to the 
population. This goal is achieved indirectly by 
extracting latent variables T and U from the factors and response, respectively, in the 
sample. The extracted factors T (also known as X-scores) are used to predict the extracted 
factors U (also known as Y-scores) and the predicted Y-scores are used to construct 
prediction for the responses in the sample. After confirming the robustness of the 
constructed prediction through cross-validation, this prediction model can be used to 
predict the response from the population.53 
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The importance of the cross-validation process 
 Cross-validation is a very important and useful tool in the classification process 
which serves two critical functions: (1) to assess the complexity of a model, i.e. is the 
number of latent variable being utilized to build the model large enough to capture 
sufficient variance from the dataset and (2) to provide an estimate of performance when 
the model is applied to unknown data. In other words, the cross-validation process is a 
“quality-control” step for the classification model. For any given dataset the cross 
validation process is a series of experiments (called sub-validation experiments) that 
starts with the removal of a subset of spectra from the dataset to form a test set, then 
construction of a model using the remaining objects in the dataset and application of 
resulting model to the objects in the test set. In this way each validation experiment 
involves testing the model with objects that are not used to build the model. Typically the 
cross-validation process involves more than one sub-validation experiments.  
The success of any cross-validation process relies on unbiased selection of test sets 
objects. Therefore several different cross-validation methods are available depending on 
the size of the dataset, and these cross-validation methods differ in how the test set 
objects are selected.  Each cross-validation method has two most important parameters, 
the splits and the iterations. The split is the total number of test sets that will be created 
and the iteration is how many times the sub-validation experiment is performed. The 
value of splits must be smaller than half of the total number of objects in the dataset, i.e. 
the number of test objects per sub-validation experiment = total number of object in data 
set/splits. For the UTI bacterial spectra dataset which consist of 150 spectra from the 12 
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strains, we employed random subsets with 27 splits and 21 iterations. These numbers are 
chosen such that there are at least 2 spectra from each of the twelve strains that 
participate in the cross-validation process.  
Using barcoded spectra as input vectors improve sensitivity and specificity 
Using the spectral second derivative-based barcodes (curvature up = 1; curvature 
down = 0) instead of the first or the raw spectra as input vectors for multivariate 
classification has been shown to results in improved sensitivity and specificity for 
bacterial strain identification.43 In this study each individual UTI bacterial SERS spectra 
is converted into barcode, or an array of one and zero based on the sign of the second 
derivative at each wavenumber. The use of barcode effectively minimizes classification 
errors due to broad baseline contributions and intensity variability between individual 
spectra resulting from the SERS substrate and all sources of biological sample 
inhomogeneity.   
Building PLS-DA predictive model with twelve UTI bacteria SERS spectra 
The result of cross-validated PLS-DA classification is shown in Figure 2-8. The 
choice of 24 LV corresponds to a number after which additional LV does not improve 
classification quality, as evident from plotting the cross-validated root mean square error 
(RMSECV) against each LV as shown in Figure S-7-1. The corresponding confusion 
matrix is given in Table S-7-3 and the sensitivity and specificity for each bacterial strain 
is shown in Table S-7-4. The analytical sensitivity (true positive rate) and specificity (true 
negative rate), averaged over all 12 classes, is 95.8% and 99.3% respectively, for this 
classification model. The average classification error for the model is just 2.3%. This 
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result demonstrates the potential for SERS spectra bacterial strains grown in urine to 
serve as a rapid (less than one hour) diagnostic at clinical concentrations.   
 
Figure 2-8 Result of a cross-validated PLS-DA classification of the SERS spectra of the twelve 
bacterial strains grown in and enriched from processed urine. The horizontal dashed line is the 
model threshold.  
 
Application of constructed PLS-DA model for diagnostic test of unknown UTI 
strain in unprocessed urine 
To test the robustness of the PLS-DA classification model using the SERS spectra 
of these twelve UTI bacteria strain grown in processed urine, a set of SERS bacteria 
spectra for one of the UTI clinical isolate, E.coli BD6594 grown and enriched in non-
processed urine is supplied to the classification as unknown. As described previously the 
urine sample used for growing this bacteria strain was not subject to prior solid material 
removal via centrifugation. The bacteria grown in this urine is enriched with the four-
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stage filtration/centrifugation system described in Figure 2-1. The resulting SERS 
spectrum is shown in Figure 2-9 and is compared to the SERS spectrum that result from 
spiking this strain into processed urine which had solid material removed by 
centrifugation prior to inoculation. Two spectrum are nearly identical.  
 
Figure 2-9 SERS spectra of different growths of E. coli BD6594 grown and enriched from 
unprocessed and processed urine. 
However, when twenty SERS spectra of these bacteria grown in unprocessed urine were 
converted into barcode and inputted as unknowns into the PLS-DA classification model 
(Figure 2-8) developed with the spectra for the twelve strains of bacteria grown in 
processed urine, the classification correctly predict E. coli BD6594 as the most probable 
bacterial strain for all twenty spectra shown in Figure 2-10. The entire procedure from 
enriching bacteria grown in unprocessed urine to correctly classify is accomplished in ~ 
50 minutes. Thus with this successful identification and with the previously determined 
drug susceptibility for this strain, our rapid spectroscopic diagnostic platform would 
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allow the physician to know which antibiotics would be effective for this patient’s UTI 
condition within one hour. Such a result would have taken more than 48 hours via the 
gold standard, cell growth procedures.   
 
Figure 2-10    Using the PLS-DA model constructed with SERS spectra of twelve UTI bacterial strain 
grown in processed urine, a set of twenty spectra of an unknown bacterial strain grown in 
unprocessed urine is correctly identified as E. coli BD6594.   
 
2.7 - Conclusion 
The results shown in this chapter demonstrate the capability of the SERS platform 
to be a rapid (< 1 hour), growth-free technique for diagnosis of UTI, and when combined 
with an a priori developed library of antimicrobial susceptibility profile for each strain, 
our SERS platform can provide strain-specific identification at clinically relevant 
infection levels which is crucial for determining the best antibiotic treatment for the 
patient. UTI diagnosis with strain identification and antibiotic specificity at 105 cfu/mL 
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level can be achieved in less than an hour via the SERS platform accurately, 
characterized by >95% sensitivity and >99% specificity even in this relatively small 
library of 12 UTI clinical UTI bacterial isolates. The SERS spectra of these bacterial 
strains grown in urine are shown to be primarily due to purine components: adenine, 
hypoxanthine, xanthine, guanine, AMP, uric acid and guanosine. The species and strain 
specific SERS signatures are due to different amount of these purine components secreted 
by the bacterial cells to the surrounding extracellular region instead of cell wall 
components as reported in many literatures previously.  The observation of purine 
metabolite as main molecule contributing to the SERS spectra in these UTI clinical 
isolates is consistent with our previous report regarding SERS spectrum from vegetative 
bacteria88. The differences in relative contributions of these purine metabolites giving rise 
to the SERS strain specificity are resulted from the absence or presence of specific 
enzymes in the purine degradation pathway as previously reported.88  
While these proof-of-principle results shows promise for developing a low-cost, 
rapid optical approach for antibiotic-specific, strain-specific UTI diagnosis, several 
challenges needed to be addressed before clinical adoption. These challenges including 
development of a low cost or reusable device for bacterial cell enrichment and separation 
from other solid urine matters. The prototype filtration system needs to be rebuilt for each 
sample to avoid cross contamination. Also more bacterial strains with antibiotic 
susceptibility profile pre-determined are needed to be added to the SERS library to ensure 
sufficient range of potential UTI pathogens. In summary, the results discussed in this 
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chapter demonstrate the potential of a SERS based technology to be developed into a 
rapid, growth-free, low-cost UTI diagnostic with strain specificity.    
 
2.8 - Extended study: Time evolution of UTI bacteria SERS signature  
Figure 2-6 shows that purine metabolites secreted by the bacterial cells to the 
surrounding extracellular region are the molecular basis for the species and strain SERS 
specificity of the UTI causative bacteria. Therefore it would not be surprising that the 
relative contribution of different purine metabolites could have a post-washing time 
dependence, since the bacterial starvation response is a multicomponent dynamic process. 
For the SERS UTI diagnostic perspective it’s also important to know how these changes 
of relative contribution affect the spectroscopic features that allows the distinction 
between different bacterial strains. In other words, the timing at when the SERS spectra 
are acquired will be important post sample washing if there are time-dependent spectral 
features change. On the other hand, these time-dependent spectral feature changes can 
serve as additional identification of the bacterial strain. All the previously discussed UTI 
clinical isolate spectra were acquired at the same post-washing time (20 min).   
Figure 2-11 and Figure 2-12 show the SERS spectra as function of time post 
washing of two of the twelve UTI E. coli strains, E. coli BD6880 and E. coli BD7023. In 
both bacterial strains the SERS spectral features appear as early as 10 minutes post 
washing, but in both strains the contribution of guanine continue to increase as evident by 
the relative ratio between the  ~725 cm-1 and the ~665 cm-1 band, corresponds to the 
unique peak of hypoxanthine and guanine respectively. As shown in the bar plot in 
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Figure 2-6, the main difference that allow distinction between these two strains is the 
difference in the relative contribution of guanine (0.07 and 0.21, respectively).  
 
Figure 2-11 SERS spectra of E. coli BD6880 as a function of time post washing. The increasing 
contribution of guanine evident from the increasing intensity of the ~ 665 cm-1 band is indicated by 
the vertical dash line.  
 
Figure 2-12 SERS spectra of E. coli BD67023 as a function of time post washing. The increasing 
contribution of guanine evident from the increasing intensity of the ~ 665 cm-1 band is indicated by 
the vertical dash line.  
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3. SERS Diagnostic Platform: Sexually Transmitted Disease 
3.1 - Chlamydia and Gonorrhea – the Silent Killer 
Sexually transmitted diseases (STDs) continue to be a significant cause of 
morbidity in the US with ~ $15.9 billion spent annually on healthcare costs related to 
their diagnosis and treatment.54  Chlamydia, the most common sexually transmitted 
disease (STD) in the US, is caused by infection from the Gram-negative bacterium C. 
trachomatis.55 More than 1.5 million cases of Chlamydia were reported to the Center for 
Disease Control and Prevention (CDC) in 2015, an increase of nearly 6% over 2014, with 
twice as many cases reported for woman than men. Recent CDC data also demonstrate an 
increase of reported Chlamydia infections in Europe, rising from 191,000 in 2004 to 
385,000 in 2013.56  About 1 in 15 sexually active young women in the US between the 
ages of 14 and 19 have already been infected once with chlamydia.57 Although most 
patients with chlamydia are asymptomatic, and hence these numbers may underrepresent 
the prevalence in the population,58 long-term, untreated chlamydia infection can lead to 
severe consequences such as pelvic inflammatory disease, a major cause of infertility, 
ectopic pregnancies and chronic pelvic pain in women.57,59  Chlamydia has been shown to 
increase the risk of HIV transmission and infection60,61 and perinatal transmission may 
result in conjunctivitis, pharyngitis and pneumonia in newborns.62, 63 In addition, C. 
trachomatis is the cause of trachoma, a major cause of preventable blindness in 
developing countries in Asia and Africa.64,65  
The C. trachomatis organism is an obligate intracellular Gram-negative bacterium 
requiring an epithelium host cell to complete its life cycle.66 It lacks the enzymes for 
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many biosynthetic and metabolic pathways, including ATP production and degradation, 
and consequently, must rely on the infected host for many nutrients and energy.67 This 
bacterium has a complex bi-phasic developmental cycle which involves a metabolically-
active and noninfectious form called reticulated body (RB) and a metabolically-inactive 
but infectious form called an elementary body (EB). Following invasion of epithelial 
cells, the EBs are converted to RBs, the intracellular replicating form of this organism. 
Approximately 20 hours after infection and after multiple divisions by binary fission, the 
RB starts to differentiate into the EB developmental stage and 48-72 hours later the 
infectious EBs are released to initiate new rounds of infection.70 Like other Gram-
negative bacteria, the C. trachomatis cell membrane is comprised of an outer and an inner 
membrane separated by a peptidoglycan layer. However, uniquely to C. trachomatis is 
the presence of an unusually thin peptidoglycan layer that normally filled up the space 
between the outer and the inner membrane in other Gram-negative bacteria. Instead, a 
protein layer, termed major outer membrane protein (MOMP) is present in that space. 
MOMP is a highly disulfide cross-linked protein that provides additional structural 
reinforcement against osmotic pressure effects68,69,70 and also acts as an anchor for many 
“accessory” protein such as those for antigen recognition and entry to host cell.70,71,72,73 
Gonorrhea is the second most commonly reported STD in the US, with ~400,000 
cases reported in 2015 and results from infection by the Gram-negative bacterium N. 
gonorrhoeae. After decades of decreasing reported rates had reached an all-time low in 
2011, the prevalence of gonorrhea in the US has shown a steady increase in the last five 
years.55  Patients with gonorrhea are often asymptomatic until complications arise such as 
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pelvic inflammatory disease, ectopic pregnancy and infertility. Untreated gonorrhea can 
also lead to disseminated gonococcal infection (DGI) when N. gonorrhoeae spreads to 
the blood or other parts of the body. 74,75 In addition, as also found for C. trachomatis, 
gonococcal infections have been shown to facilitate the transmission of HIV infection.76 
The emergence and spread of multi-drug resistant N. gonorrhoeae strains is an 
increasingly recognized problem for effective treatment of gonorrhea.55,77 Furthermore, 
~30% of patients infected with N. gonorrhoeae are co-infected with C. trachomatis.78 
Consequently, patients treated for gonococcal infection are often routinely treated with an 
antibiotic regimen that is effective against C. trachomatis infection as well.79  
 
3.2 – Current Chlamydia and Gonorrhea Diagnostic Methods 
Direct detection of C. trachomatis and N. gonorrhoeae can be achieved by culture 
and non-culture methods. Cell culture method, long the reference standard for chlamydia 
and gonorrhea diagnosis, requires specialized culture medium and culture conditions, 
skilled staff for the technically-demanding procedures and is very slow (≥ 72 hours), 
making it virtually impossible for routine and point-of-care diagnostics.80,81 Similarly, N. 
gonorrhoeae is also a fastidious organism requiring enriched media in a CO2 atmosphere 
for lab cultured growth for ≥ 48 hours. Alternatively, non-culture methods include 
enzyme immunoassay (EIA) which detects the chlamydial lipopolysaccharide or the 
major outer membrane protein (MOMP), and direct fluorescent antibody stain (DFA) are 
available and had largely replaced the cell culture method as standard diagnostic methods 
for chlamydia and for gonorrhea.81,82,83 Nucleic acid amplification tests (NAAT) are the 
 41 
current best technology recommended by the CDC for the detection of chlamydia and 
gonorrhea.81 NAAT is a growth-free diagnostic offering sensitivity and specificity 
comparable to culturing with a faster turnaround time.84 However, the susceptibility to 
cross-contamination from exogenous genetic material, cost, inability to distinguish 
bacterial viability (i.e. live vs. dead cells), the presence of inhibitory factors and the need 
for experienced technicians in laboratory settings, which necessitates a second clinical 
visit for some patients, are limitations for the NAAT approach.58, 85 , 86  Given the 
asymptomatic nature of many chlamydia and gonorrhea infections, screening is 
recognized as the most effective approach for reducing the societal and personal impact 
of these diseases.81,84 Thus, the development of alternative, low-cost, easy-to-use, rapid, 
point-of-care approaches for the detection and simultaneously differentiate C. 
trachomatis and N. gonorrhoeae in clinical setting and in a useful timeframe (≤ one hour) 
for narrow spectrum antibiotic drug prescription remains a critical strategy for improving 
reproductive and sexual health worldwide.  
Here, we report for the first time on the potential ability of SERS to provide rapid, 
growth-free, detection and identification of the Chlamydia and gonorrhea etiological 
agents, C. trachomatis (EBs) and N. gonorrhoeae. The SERS spectra of these bacterial 
cells are studied as a function of nanoparticle metal (Ag and Au), sample concentration 
and time from sample enrichment.  The molecular and biochemical origins of the SERS 
vibrational signatures of these two Gram-negative microorganisms are found to be very 
different reflecting their significantly distinct bacterial lifestyles.  These results will be 
compared and contrasted to our previous SERS studies, and in terms of our fundamental 
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understanding of the interaction of bacterial cells and metal nanoparticles.  The prospects 
for the development of a SERS based platform for rapid (< one hour), low-cost STD 
diagnostic are promising given the data presented here.   
 
3.3 – Materials and Methods 
SERS active substrate All SERS spectra reported here were obtained using in-situ 
grown, aggregated Au or Ag nanoparticle covered SiO2 substrates previously developed 
in our laboratory.34 Details concerning the production and description of these SERS 
active chips, and the characterization of their performance for providing reproducible 
SERS spectra of bacteria have been described in previously.34,43,44,47,48,49,50,87,88,89.  These 
nanostructured substrates result from a two-stage reduction of a metal ion doped sol-gel, 
producing small (2 – 15 particles) aggregates of monodispersed ~80 -100 nm Au or Ag 
nanoparticles covering the outer layer of ~1 mm2 SiO2 substrate.  The SEM images of the 
aggregated Au or Ag nanoparticles on the SiO2 substrate are shown in Figure 3-1 and 
Figure 2-2.  
 
 
Figure 3-1  SEM image of the aggregated Ag nanoparticles-covered SiO2 substrate. 
 43 
In vitro cultivation of C. trachomatis C. trachomatis D/UW-3/CX (VR-885) was 
obtained from American Type Culture Collection (ATCC®, Manassas, VA). The McCoy 
cell line, CRL-1696, (ATCC®) was used as the host cell. McCoy cells are grown in 
minimal essential medium (MEM) containing 10% fetal bovine serum (ATCC®) in a 
humidified incubator at 37 °C and 5% CO2 until 90%-100% confluent. After the McCoy 
cells are infected a special maintenance medium is prepared with the following 
ingredients: 90 mL DMEM (Life Technologies®), 10 mL fetal bovine serum (ATCC®) 
and 1 µg/mL cycloheximide (Sigma®). Addition of cycloheximide inhibits the growth 
the host cell and allows nutrients to be directed to the proliferating C. trachcomatis cells. 
The procedure for C. trachomatis in vitro cultivation and harvest is described in 
Appendix 8.4. The harvest C. trachomatis are aliquoted and stored in Hank Balanced Salt 
Solution (HBSS) at -80 °C.  
Processing C. trachomatis cells for SERS spectral acquisition   To prepare C. 
trachomatis for SERS spectra acquisition, an aliquot (100 µL) is removed from -80 °C 
sample supply and quickly thawed at room temperature (< 30 seconds). The sample is 
then centrifuged at x23,000g (Eppendorf®) for 4 minutes at 4 °C and the HBSS 
supernatant is removed after centrifugation. The pellet at the bottom, which mainly 
consists of C. trachomatis EBs and a small amount of RBs, is washed four times with 10 
µL ice-cold deionized water each time. Between washes the sample is centrifuged at x 
23,000g (Eppendorf ®) for 4 minutes at 4°C.  The chlamydial EB has a layer of disulfide-
bonded protein at its membrane as compare to other Gram negative bacteria,68,69 while 
the RB has fragile cell membrane and will not be able to withstand the osmotic pressure 
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from pure water. Therefore the RB will be lysed and removed during the washing process, 
leaving only EBs behind. After the last wash, the pellet is dispersed in 5 µL ice-cold 
deionized water by pipetting and vortexing. For acquisition of SERS spectra, 1 µL 
sample is added to the SERS active substrate and air-dried for 5-10 minutes.  
Processing N. gonorrhoeae cells for SERS spectral acquisition    N. gonorrhoeae 
(FA1090) is obtained from ATCC®. The agar medium is chocolate II agar plate with 
IsoVitaleX® enrichment and is commercially available (BD®). The cultivation and 
harvest procedure for this bacterial strain is described in Appendix 8.3. To prepare the 
bacterial cells for SERS spectra acquisition, the harvested bacteria are placed in a 2 mL 
micro-centrifuge tube containing 0.5 mL ice-cold deionized water immediately after 
being stripped off from the plate. The bacteria are washed four times with 0.5 mL ice-
cold water and centrifuged at x4500g at 4 °C between each wash.  After last wash the 
bacteria pellet is dispersed in about 50 µL ice-cold water by vortexing. The amount of 
bacteria in this 50 µL sample is determined to be ~ 107 ifu/mL by serial dilution and 
overnight culture.  1 µL sample is added to the SERS active substrate and air-dried for ~ 
5 minutes before spectral acquisition.  
SERS spectral acquisition and data processing  All SERS spectra reported here were 
acquired with an RM-2000 Renishaw Raman microscope employing a 50x (infinity-
corrected, 0.75 numerical aperture) objective and 785 nm excitation. Incident laser 
powers of ~ 3.3 mw and ~10 seconds of illumination time were used to obtain the 
reported bacterial SERS spectra. Typically ten spectra per sample were obtained for each 
experimentally reported spectrum. Spectral acquisition took less than 10 min.  The 
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illuminated Raman excitation field of view was ~30 µm x 6 µm. The 520 cm-1 band of a 
silicon wafer was used for frequency calibration. Peak frequency precision is ± 0.5 cm-1. 
The acquired spectra are averaged and baseline corrected with GRAMS® (Thermo®). 
The SERS spectra are normalized and plotted via MATLAB® and the spectra are 
vertically offset for clarity.  
 
3.4 – Results and Discussion 
Differentiation of C. trachomatis and N. gonorrhoeae by vibrational signatures on 
gold and silver SERS active substrates 
SERS spectra of C. trachomatis and N. gonorrhoeae on the gold and silver 
nanoparticle covered SiO2 SERS substrates excited at 785 nm are shown in Figure 3-2.  
 
Figure 3-2   Compare C. trachomatis (top) and N. gonorrhoeae (bottom) SERS spectra on the 
gold and the silver substrate.  
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Three important points are illustrated in this figure. Firstly, N. gonorrhoeae and C. 
trachomatis can be clearly distinguished from each other through their spectral features 
on the gold and silver SERS active substrates right after sample washing (t = 0 min). This 
means these two bacteria can be distinguished as soon as a washed sample is placed on 
the substrate and a SERS spectrum is acquired on either the gold or the silver substrate. 
Secondly, this figure shows that the SERS spectra of the same bacteria can be quite 
different on different metal substrates. For example, the SERS gold spectrum of C. 
trachomatis is dramatically different from its SERS silver spectrum, and the overall 
intensity and S/N ratio for the silver spectrum is much weaker than the gold spectrum. On 
the gold spectrum three broad vibrational features center around ~1550 cm-1, ~1200 cm-1 
and ~ 900 cm-1 are observed. These three broad features are not observed on the silver 
spectrum; instead discreet, narrower vibrational bands are seen. On the other hand, the 
SERS gold and silver spectrum of N. gonorrhoeae is relatively similar. The overall signal 
intensity for the gold and for the silver spectra are also similar. Thirdly, N. gonorrhoeae 
and C. trachomatis display different time-dependent signal intensity and spectral feature 
changes on both metal substrates, which can be used as additional revenue to distinguish 
these two bacteria. On the gold substrate C. trachomatis shows a decrease of overall 
signal intensity by 80% over the course of one hour while on the silver the signal 
intensity remains relatively constant. On the other hand, prominent spectral feature 
changes can be seen on both the gold and the silver spectra for N. gonorrhoeae, example 
by the disappearance of the ~ 1030 cm-1 band at t = 60 min spectra and the blue shift 
from 733 cm-1 to 736 cm-1. These time-dependent signal intensity and spectral features 
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changes will be discussed below. Figure 3-2 powerfully demonstrates the prospect of the 
SERS methodology as a label-free, growth-free, rapid diagnostic method with potential 
in-clinic use when combining a portable instrument and an effective bacterial cell 
isolation and enrichment procedure from patient samples. Consequently, a physician can 
arrive to a diagnostic decision in ~40 min, with most of this time is spent on sample 
preparation in the current prototype procedure. In contrast the current non-culture 
genotype-based techniques required ~2-4 hours sample preparation time in laboratory 
setting before obtaining results.55,56,57,58 Moreover, the physician will also be able to 
distinguish a chlamydia infection from a gonorrhea infection through comparison of the 
SERS gold and silver spectral features from one isolated bacterial cell sample. This is 
valuable because up to 40% patients infected with chlamydia are also infected with 
gonorrhea, and the current diagnostic methods require the test for gonorrhea to be 
performed before test for chlamydia to avoid cross-contamination and false negative.55,58  
 The sensitivities for C. trachomatis and N. gonorrhoeae on the gold and silver 
substrates are shown in Figure S-7-2 and Figure S-7-3, respectively. Serial dilution on 
washed bacteria sample was performed to determine the sensitivity. Quantitation of 
bacterial cells in undiluted sample was determined through serial dilution and overnight 
cell culture growth and colony counting. For C. trachomatis the lowest concentration of 
EBs to yield a SERS signal on the gold and silver substrates was determined to be ~ 
5x104 ifu/mL and ~102 ifu/mL, respectively. For comparison, the chlamydial loads 
determined by genotype-based techniques in first-void urine specimens in infected patient 
range from ~101 to 105 EB/mL, and ~104 EB/mL for vulvo-vaginal swabs as reported in  
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clinical studies.90,91 Therefore the sensitivity of our SERS substrates for the chlamydial 
EB falls within the range of typical EB concentration found in patient samples. For N. 
gonorrhoeae the lowest concentration to yield a SERS signal on the gold and silver 
substrate is ~106 cfu/mL. For comparison, N. gonorrhoeae loads found in urine in 
infected patient range from ~104 - 106 in these studies. 92,93 Thus, our SERS sensitivity 
for N. gonorrhoeae is at the upper limit of the clinical concentration.  However ~106 is 
the concentration of enriched bacteria, and with effective enrichment procedure such 
concentrations can be achieved as demonstrated above for the UTI samples.   
In summary, we have demonstrated the advantages of ease-to-use, multiplexing-
capability, specificity and sensitivity with our SERS methodology for potentially point-
of-care diagnostic of C. trachomatis and N. gonorrhea, the causative agent for the two 
most common sexually transmitted diseases worldwide. The ability to distinguish these 
two bacteria using differences in the vibrational features on gold and silver SERS 
substrates is shown. In the next section we will discuss the molecular origins of these 
vibrational features as well as the observed spectral feature changes. Understanding 
molecular mechanism behind these is crucial not only to explain the SERS observations, 
but also to demonstrate the potential of SERS to be a powerful bioanalytical probe for 
understanding dynamic biological activity of these bacteria at the molecular level.   
 
The identities of the molecules contributing to the SERS spectra  
 The location (i.e. extracellular vs. intracellular) of the molecules contributing to 
the SERS spectrum provides information on the identity of possible molecular candidates 
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that are responsible for the observed SERS signal. To understand where these SERS 
molecular contributors are for the N. gonorrhoeae SERS spectrum, we compared the 
SRES spectrum on the gold and the silver substrate acquired from the cells and from the 
supernatant surrounding the cells. The sample are centrifuged at t = 0 min (immediately 
after washing), 30 min and 60 min post-washing and a portion of the supernatant is 
removed from the bacterial cells. The supernatant SERS spectra are compared to the cell 
spectra acquired at the same time point.  
 
Figure 3-3 Gold and silver SERS spectra comparing the signal from N. gonorrhoeae cell and 
from the unfiltered supernatant fluid around the cell as a function of time post sample processing.  
As shown in Figure 3-3, initially (t = 0 min) the molecules contributing to the N. 
gonorrhoeae spectra are located on the bacterial cell. At t = 30 min spectral features start 
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to appear in the SERS spectra of the supernatant. This implies that molecules are 
beginning to be secreted into the supernatant and providing the SERS spectrum of N. 
gonorrhoeae. At t = 60 min molecules contributing to the SERS spectrum are located on 
both in the supernatant and on the cell spectra, but the change of the spectral features, 
notably the disappearance of the ~1030 cm-1 band and the blue-shift 733 cm-1 to 735 cm-1, 
indicates that a different set of molecules are dominating the SERS spectrum at t = 60 
minutes, as compare to t = 30 minutes. The observation that SERS spectra are dominated 
by molecules secreted by bacterial cells has been previously reported by the Ziegler 
lab,34,47,48,49,50,87,88,89 Bacterial SERS spectra have been attributed  to seven purine 
metabolites secreted by the bacteria to the surrounding as a response to the stress or 
starvation conditions.  Best-fitting the observed bacterial spectra to a linear combination 
of these purine molecular component spectra44,88,89 is used to determine the relative 
contribution of these seven purine metabolites in each bacterial spectra. In this STD study 
we use the same best-fit calculation method to decipher the identity and relative 
contribution of the key SERS molecular contributor for each time point and for the gold 
and the silver SERS spectrum, as shown in Figure 3-4. Two purine metabolites, adenine 
and guanine, and a third molecule, nicotinamide adenine dinucleotide (NAD), are 
identified from the N. gonorrhoeae spectra. Their relative contribution at each time point 
and on the gold and the silver substrate are demonstrated graphically in Figure 3-4 as 
well as numerically in Table 3-1. The normalized SERS spectra of adenine, guanine and 
NAD used for the calculation are shown in Figure S-7-7. We note that there’s no 
distinction between the oxidized NAD form and the reduced NADH form, therefore we 
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denoted this component as NAD/NADH in the figure. The disappearances of the ~1030 
cm-1 band as well the blue-shifts of the 733 cm-1 is attributed to the change of relative 
contribution of NAD/NADH after 60 minutes post washing. N. gonorrhoeae is the first 
bacterial species that we have encountered that shows NAD/NADH vibrational features 
in addition to purine metabolites. It is also the first species we reported to display a time-
dependent change of spectral features due to change of relative contribution of the key 
SERS molecular contributors. Our next discussion will focus on why NAD/NADH 
appears at the earliest times but seemingly disappears from the SERS spectrum at later 
times and the possible molecular origin of this molecule.  
 
Figure 3-4 The gold and silver SERS spectra of N. gonorrhoeae as a function of time post 
washing are shown with their best-fit calculated by a linear combination of three purine components: 
adenine, nicotinamide adenine dinucleotide (NAD/NADH) and guanine. 
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 time  (min) adenine guanine NAD/NADH 
On gold 0 0.25 0 0.75 
30 0.43 0.02 0.55 
60 0.8 0.2 0 
On silver 0 0.85 0 0.15 
30 0.93 0.05 0.02 
60 0.95 0.05 0 
Table 3-1 Contribution of purine metabolite to gold and silver N. gonorrhoeae spectra at each 
time point determined by linear combination of the normalized component spectra.  
 To understand the disappearance of NAD/NADH at the later time point (t = 60 
min), a N. gonorrhoeae sample which had been left at room temperature for 60 minute 
following an initial wash with ice-cold water was washed with ice-cold water again and a 
SERS spectrum of the bacteria cells was obtained, as shown in Figure 3-5 (left). We see 
the re-appearance of NAD/NADH spectrum and the spectral features are nearly identical 
to the N. gonorrhoeae on gold spectrum at t = 0 min. This observation shows that 
NAD/NADH molecules are bound to the bacterial cell membrane and therefore should be 
seen in spectra of N. gonorrhoeae at all the time points. The NAD/NADH features seem 
to disappear from the t = 60 min because their features are masked by the more intense 
adenine and guanine SERS bands. Adenine and guanine are excreted to the surrounding 
supernatant as response to the low nutrient condition, therefore when the bacteria cell are 
dried onto the SERS substrate these molecules are close to the surface of the gold 
nanoparticles than NAD/NADH, which are bound to the cell membrane. In addition, both 
adenine and guanine have greater Raman cross-sections on the gold and silver SERS 
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substrates than NAD/NADH as shown in Figure S-7-8. Therefore the spectral features 
from NAD/NADH are not evident when the SERS spectrum is dominated by adenine and 
guanine at t = 60 min.  When adenine and guanine are washed away at t = 60 min, the 
NAD/NADH features reappear. This re-washing experiment also ensures that the 
NAD/NADH observed in the N. gonorrhoeae spectra are from these molecules bound to 
the cell membrane instead of being due to remaining material from the growth plate since 
the IsoVitaleX® supplement to the agar plate contains NAD. The appearance of 
NAD/NADH is unique to N. gonorrhoeae, at least in this limited comparison between 
Gram-positive S. aureus Newman and three Gram-negative E.coli clinical isolates89 
shown in Figure 3-5 (right). All the bacteria strains are grown on chocolate agar plates 
with IsoVitaleX® (BD) supplement. This shows the presence of NAD/NADH is a unique 
property of N. gonorrhoeae cell membranes.  
 NAD/NADH is a co-substrate for many membrane-bound enzymes that are 
critical for the growth of N. gonorrhoeae in the human body. Examples are NADH 
dehydrogenase (EC 1.6.99.3) and NAD(P)H oxidase (EC 1.6.99.1), which are enzymes 
that defend the bacteria against reactive oxygen species (O2-) in the mucosal surface 
environment and from the host local inflammatory response.94,95 The observed bounded 
NAD/NADH are the co-substrates for these enzymes. In addition, it’s also known that in 
vitro growth of N. gonorrhoeae requires two essential growth factors in addition to 
standard bacterial growth medium: lysed red blood cells and NAD.  The lysed red blood 
cells serve as the primary source of iron which is an essential metal for many enzymes. 
However, the oxidation state of iron is Fe3+ (hence the “chocolate” color of the agar plate) 
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which can form insoluble Fe(OH)3 under physiological condition. Therefore Fe3+ ion 
must be converted into Fe2+ which is soluble under physiological condition, and 
NAD/NADH can serve as the electron donor Fe3+ ion. 96 , 97  Thus the observed 
NAD/NADH signal could be the co-substrate for the enzyme that catalyzed the reduction 
of Fe3+. In the absence of an iron source some of the NAD/NADH may be released from 
the enzyme therefore explaining the presence of NAD/NADH features in the supernatant 
at t = 30 min. In summary, Figure 3-4 demonstrates the potential of our SERS 
methodology not only as a disease diagnostic platform but also a powerful bioanalytical 
tool for studying enzymatic processes at the outer cell membrane region of bacterial cells 
when the bacteria are placed in a low-nutrient environment. 
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Figure 3-5  (Left) Comparing the gold SERS spectra from N. gonorrhoeae from the cell and 
from the supernatant at t = 0 min (initial wash) and after re-washing at t = 60 min further show that 
the NAD/NADH molecules are bound to the bacteria cell membrane. 
 (Right) Comparing gold SERS spectra at t = 0 min from the cell of S. aureus Newman (Gram-
positive), N. gonorrhoeae (Gram-negative) and three E. coli (Gram-negative) strains grown on 
chocolate agar plat with IsoVitaleX® show that the appearance of NAD/NADH features is unique to 
N. gonorrhoeae only. All bacteria cells are re-washed with ice-cold water after left at room 
temperature 60 minutes and the NAD/NADH features re-appear only on N. gonorrhoeae.   
 On the other hand, comparing the SERS spectra from C. trachomatis cells with 
the spectra from the supernatant as shown in Figure 3-6 reveals that the molecules 
contributing to the SERS spectra are located on the cell but not in the supernatant. 
Furthermore, monitoring the supernatant spectra as a function of time post-washing 
shows that these SERS contributors are always on the cell immediately after washing up 
to an hour post washing on both metal SERS substrates as shown in Figure S-7-4. This 
means the molecules contributing to the C. trachomatis spectra are securely anchored 
onto the cell membrane.  This observation is thus consistent with the origin of these 
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molecules to be the bacterial cell membrane component or the ‘accessory’ molecules 
connected to the cell membrane.  
 
Figure 3-6 Comparing the SERS gold and silver spectra from C. trachomatis cell with the 
spectra from the supernatant reveal that the molecule contributing the spectra locates only on the 
cells. Compare with spectra from HSA and avidin show that protein molecules on the cell membrane 
are the major contributor to the SERS spectra of C. trachomatis.  
In order to determine the molecular origins of these C. trachomatis signal we first 
consider the structure of C. trachomatis cell membrane. As mentioned previously, unique 
to C. trachomatis is the presence of MOMP that fill up the space in between the outer and 
the inner cell membrane in addition to an unusually thin peptidoglycan layer. MOMP is a 
highly disulfide cross-linked protein that serves as an anchor for many “accessory” 
proteins such as those for antigen recognition and entry to host cell.71,72,73 Thus, we 
hypothesize that the main contributors to our C. trachomatis SERS spectra are protein 
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molecules on the C. trachomatis cell membrane. Because it’s very difficult and costly to 
isolate each of the protein components of the C. trachomatis membrane to acquire SERS 
spectra at this preliminary stage, we use commercially available protein molecules as 
models instead. Human serum albumin (HSA) and avidin from chicken egg white (avidin) 
are selected as protein model compounds. HSA, a three-domain protein consist of mostly 
alpha helices, is selected because HSA is a model protein molecule used in studying 
metal-protein interactions in literature. 133,134,135 Avidin is chosen because it has similar 
size (i.e. molecular weight) as HSA but is consists of mainly beta-sheets. Both proteins 
are available commercially as lyophilized powder. Solutions of both proteins are freshly 
prepared in deionized water prior to each SERS experiment. For the gold substrate the 
protein solution concentration is 100 µM.   However, we found that on the silver 
substrate lower protein concentration (1 µM or less) yields greater SERS intensities and 
larger S/N ratios. Therefore for the silver substrate the protein solution concentration is 
10 nM. Comparison of the SERS spectra of the two proteins and C. trachomatis cell 
spectra are shown in Figure 3-6. We can clearly see the similarity between the C. 
trachomatis cell and the two protein SERS spectra, indicating that the main SERS 
molecular contributors of C. trachomatis spectra are protein molecules on both 
nanostructure metals. However, C. trachomatis can still be distinguished from the two 
proteins on both metals. For example, the difference in relative peak intensity ratio 
between the three broad features on the gold spectra, as well as the presence/absence and 
the peak intensity of the ~610 cm-1 band on the silver substrate can be used to distinguish 
these samples.  
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 The three vibrational features (center around ~ 900 cm-1, ~1200 cm-1 and ~1550 
cm-1) on the gold spectra for C. trachomatis and the proteins are very broad (~ 150 cm-1), 
suggesting  that these features are due highly inhomogeneous molecular systems as might 
be expected for protein aggregates.  To investigate this hypothesis we acquired  dynamic 
light scattering spectra of the same HSA solution that show these broad SERS features, 
and the results (see Chapter 4) had lead us to conclude that these broad features are in 
fact due to protein aggregates created during the solution preparation process. More 
specifically, these protein aggregates are formed when their tertiary structure is perturbed 
due to the mechanical stress occurring when the protein solution is repetitively and 
vigorously pipetted.98,99,100,101 For C. trachomatis, this is happens when the centrifuged 
bacterial cells are re-suspended in water after each centrifugation step during the washing 
process. The re-suspension is achieved by pipetting to disperse the cell pellet which 
causes aggregation of the protein molecules on the outer layer of the cell membrane. This 
can also explain the decrease of overall signal intensity on C. trachomatis as a function of 
time post washing. Following the last washing step, the tertiary structures of the proteins 
at the outer layer are perturbed by pipetting and aggregations are formed.  However,   
when the sample is left undisturbed over time these protein molecules may re-arrange 
themselves back to their native tertiary structure, therefore the aggregated protein signal 
(i.e. the three broad features on gold spectrum) intensity decreases as a function of time. 
On the other hand, on the silver substrate, these broad aggregated protein vibrational 
features are not observed. Instead, discreet, more typically shaped vibrational features can 
be seen. The assignments for these bands on the silver substrate are listed in Table 3-2. 
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These features can be attributed to individual amino acids and molecular moieties, for 
example phenylalanine, tryptophan, the C-S stretch and CO2- and CH2 bending 
vibrational modes. We attribute this metal dependence of the protein signal to the more 
strongly perturbative nature of silver nanoparticles interacting with proteins.  
Band frequency on Ct 
silver SERS spectrum  
Band assignment 102, 103, 104, 105, 106, 107, 108, 109, 110, 
111* 
610 ν(CS) PH-T 
936 ν(C-COO-) 
1004 Phe (ν12) 
1035 In-plane C-H deformation of mono-substituted 
benzene ring**  
1385 ν(COO-) 
1450 δ(CH2)  
1600 Trpw1, Tyr, and/or Phe (ν8a) 
Table 3-2  Band Assignment for Silver C. trachomatis SERS spectrum.  
* References of the band assignments 
 From the results shown in Figure 3-4 and Figure 3-6 we can how the SERS results 
reflect the different “lifestyles” of these two STD causing bacteria. All bacterial strains 
studied in the Ziegler lab previously 34,43,44,47,48,49,50,87,88,89 had shown purine metabolites 
as main contributors to their SERS spectra. We generalized that bacteria release purine 
metabolites as a rapid response to low nutrient conditions, and their purine metabolism 
KEGG pathway for purine degradation can be used as guideline to predict what purine 
molecule will be produced.88 For example, the KEGG pathway for purine metabolism of 
N. gonorrhoeae is shown in Figure 3-7, and from the pathway we can see the bacteria can 
produce adenine and guanine when nucleotides are degraded.  This matches our SERS 
observation in Figure 3-4 which is just a linear combination of these two purine free 
bases and NAD/NADH. However, C. trachomatis is an exception to all previously 
observed SERS spectra. It shows membrane protein components instead of purine 
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metabolites as main contributor to the SERS spectra. C. trachomatis is an obligate 
intracellular pathogen which solely depends on the host cell for nutrient and energy 
supply,112,113 and its KEGG purine degradation pathway reflects its parasitic lifestyle. As 
shown in Figure 3-7 C. trachomatis lacks all enzymes for the appearance of AMP, GMP 
and INP, the key molecules to the purine degradation pathway. Furthermore, this species 
lacks the necessary enzymes for the degradation of these nucleotides to the free purine 
bases. This means C. trachomatis are unable to produce the purine metabolites through 
its KEGG degradation pathway, therefore no purine metabolites are observed from its 
SERS spectra.   
 
Figure 3-7  Comparing the KEGG purine degradation pathway for C. trachomatis and N. 
gonorrhoeae.  
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3.5  - Conclusion and Future work 
As a proof of concept for the development of SERS as a rapid STD diagnostic, the 
results discussed in this chapter demonstrate the potential of our SERS-based platform for 
label-free, growth-free, whole-cell diagnostic tool for rapid detection and differentiation 
of C. trachomatis and N. gonorrhoeae, which are responsible for the two most common 
underdiagnosed STDs that affect millions people and result in billions dollar healthcare 
cost annually. By compare and contrast the unique SERS vibrational signatures on our 
gold and silver substrates, we were able to distinguish these two bacteria based on their 
vibrational features. When combine with a portable instrument and an effective bacterial 
cell enrichment procedure, potentially the physician can obtain the rest in the clinical 
setting in ~40 min. We are able to decipher the main SERS molecular contributors to the 
observed SERS spectra and demonstrate the ability of our SERS-based platform as a 
novel analytical probe for studying metabolic activity near extracellular region. Our 
SERS-based platform can provide a rapid, ease-to-use, specific diagnostic methodology 
without the need of slow and technically-demanding cell growth or sample labeling.  
The details regarding the protein aggregation that was first observed in the C. 
trachomatis spectra are discussed in Chapter 4. The possible molecular origin of the 
broad spectral features on the gold substrate that seem ubiquitous across multiple protein 
samples will also be discussed in the subsequent chapter. Future work on this project will 
be directed toward expanding our SERS reference library with more STD related 
bacterial strains to test this methodology for strain specificity. Another important aspect 
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will be to work on an effective enrichment procedure to isolate bacterial cells from 
patient samples at clinically relevant concentrations.  
 
4. The SERS Vibrational Signature of Proteins 
4.1  - Introduction to SERS study of proteins 
Protein stability in aqueous solution is an increasingly important issue particularly 
in the pharmaceutical field as the number of therapeutic protein drugs has development 
increased dramatically over the past two decades. 114 Protein drugs provide critical 
treatments in numerous health conditions and diseases (e.g. diabetes, cancer, 
cardiovascular disease, autoimmune disease). However if the protein drug molecule is not 
stable in aqueous solution and forms aggregates, its biological activity and thus its 
therapeutic value diminishes.115 Moreover, accumulation of these aggregated proteins in 
body tissues can cause damage to the human body. Therefore it’s important to monitor 
the state of protein structure in aqueous solution for both treatment efficacy and human 
health concerns.  
  Vibrational spectroscopies such as IR and Raman spectroscopy are valuable tools 
for analysis of protein structure. Since the vibrational frequencies depend molecular 
structure, IR and Raman spectroscopy can provide a good estimate of the secondary 
structures of proteins in aqueous solution. The composition of secondary structures in a 
particular protein molecule may be determined by inspection of the frequencies of amide 
bands. Nine normal modes (A, B, and I-VII in the order of decreasing frequency) are 
allowed for amide bond of proteins. Table 4-1 lists the frequency and vibrational 
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assignments of the amide bands relevant to protein structure analysis by IR and Raman 
spectroscopy. Among them Amide I, II and III are the most recognizable amide bands in 
the spectrum when exited by visible light and therefore are frequently employed for 
determination of the secondary structures of protein molecules.116,117 Table 4-2 lists the 
typical frequencies of Amide I, II and III in different secondary structures. Additionally, 
the precise vibrational frequencies of the disulfide bride (500-550 cm-1 region) and 
aromatic amino acid residues tryptophan (Trp), tyrosine (Tyr), phenylalanine (Phe) and 
histidine (His) are useful for probing the local chemical environments around these amino 
acid residues and hence the microenvironment inside the protein molecule. 116, Thus IR 
and Raman are popular tools for studying the kinetic of protein aggregation formation. 122, 
118, 119, 120 Information provided by IR and Raman spectroscopy are complimentary to 
each other since some vibrational modes are IR-active and some are Raman-active, 
however a disadvantage of IR relative to Raman is the strong absorption of water at 
~1650 cm-1 which is at the frequency of the Amide I band.  In contrast, water is a 
relatively weak Raman scatter and especially so for SERS.  Water bands typically do not 
appear in SERS spectra of aqueous solutions. 
Name Frequency  (cm-1)  Vibrational motion Reference 
Amide A 3270 - 3310 >95% N-H stretch, part of a Fermi 
resonance doublet 
121,122 
Amide B 3030 - 3100 Intramolecular H-bonded N-H 
stretch, part of a Fermi resonance 
doublet, weaker than Amide A 
121, 123 
Amide I ~ 1650 80% C=O stretching 116,117 
Amide II  ~ 1550 60% N-H bend, 40% C-N stretch 116,117 
Amide III 1200 - 1400  40% C-N stretch, 30% N-H stretch 116,117 
Table 4-1 The frequency and vibrational assignment of Amide A, B and I-III relevant to the 
protein structural analysis by IR and Raman spectroscopy. 
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Conformation 
 
α-helix 
 
Antiparallel  
β sheet 
Parallel β 
sheet 
Turn Unordered 
Amide I  
(cm-1) 
1650 - 1657 1612-1640 
1670-1690 
(weak) 
1626-1640 1655-1675 
1680-1696 
1640-1651 
Amide II  
 
Centered on ~1550 cm-1, weak band and cannot be observed in the 
absence of resonance excitation. Not affected by side-chain 
vibrations.   
Amide III  
(cm-1) 
1270-1330 1229-1235 1243-1253 
Table 4-2 Frequencies of Amide I, II and III bands for different secondary structures.116,117   
The SERS spectra of proteins were previously discussed in Chapter 4 in order to 
understand the molecular origins of the SERS spectrum of C. trachomatis cells on gold 
nanostructured substrates. The similarity between the SERS gold and silver spectra of the 
bacterial cells and two proteins, human serum albumin (HSA) and avidin, lead to the 
conclusion that the main molecular contributor to the SERS spectra of C. trachomatis 
were the cell membrane proteins (Figure 3-6). The SERS spectra of these proteins and the 
C. trachomatis on gold were characterized by three broad spectral features centered 
around 1550 cm-1, 1150 cm-1 and 850 cm-1 while their silver SERS spectra display 
narrower vibrational bands assigned to vibrational motions of C-H, C-S, COO- and 
aromatic amino acid residues Phe, Trp and Tyr (Table 3-2). The broad spectral features 
on the gold SERS spectrum were shown to be attributable to aggregated protein 
molecules created during the sample preparation process. This chapter will describe the 
discovery process that leads to this conclusion in greater detail as well as providing 
additional explanation of why the gold and silver SERS spectral features of the same 
protein molecule are dramatically different. In addition to the SERS results, the presence 
of aggregated protein will be confirmed by dynamic light scattering (DLS) measurements. 
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4.2  - Materials and Methods 
SERS active substrate The SERS spectra reported here are obtained using in-situ 
grown, aggregated Au or Ag nanoparticle covered SiO2 substrate described extensively in 
the previous two chapters and prior publications from our laboratory.34,44,47,48,49,50,87,88,89 
For SERS spectral acquisitions, 1 µL of the protein solution was added to the SERS 
substrate (gold or silver) and allowed to air dry (~5 minutes) at room temperature.  
Protein solution preparation All protein molecules used in the study are obtained 
from Sigma® as lyophilized power and used directly. The lyophilized power are stored at 
4 °C or -20 °C according to manufacturer’s instruction. Unless otherwise indicated the 
concentration of protein solution used for SERS gold experiment is 50 µM and for SERS 
silver experiment is < 1 µM. The solutions are prepared by adding the solvent (water, 
saline, phosphate buffered saline (PBS)) to the lyophilized powder in 2 mL micro-
centrifuge tube. Rehydration of the lyophilized powder is accomplished by pipetting or 
inverting the micro-centrifuge tube. No sonication or vortex is used. All solutions are 
freshly prepared within one hour prior to the experiment and left at room temperature 
after preparation.  
SERS spectra acquisition  SERS gold and silver spectra are acquired with an 
RM-2000 Renishaw Raman microscope with 50x objective. A 785 nm excitation with 
incident laser power of ~3.3 mW over ~ 30 µm x 6 µm illuminated Raman excitation 
field of view and 10 seconds illumination time are used to obtain the protein SERS 
spectra. Ten spectra per sample are obtained. The peak frequency precision is ± 0.5 cm-1.  
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SERS spectra processing and baseline correction  The acquired SERS spectra 
are averaged and baseline corrected with GRAMS®. The SERS spectra are normalized 
and plotted with MATLAB® (release R2016) and displayed vertically offset for clarity.  
 In Figure 4-3 where the “generic” broad spectral features on the gold SERS 
spectrum are removed to show the weaker, narrower bands, the broad spectral features 
are treated as baseline and removed by the MATLAB function msbackadj. Msbackadj 
corrects baseline of signal with peaks that can’t be satisfactorily removed without altering 
the peaks via the more traditional polynomial fittings procedure of baseline 
corrections.124 The quality of baseline removal by msbackadj is monitored by over-
lapping the original SERS spectrum and the calculated baseline and the optimal 
parameters for msbackadj function are selected during this process.    
Dynamic Light Scattering Measurements (DLS)  The presence of protein 
aggregates in the solution upon vigorous agitation was identified and confirmed by 
making simultaneous SERS and a DLS measurements of the same protein solutions. The 
DLS measurements are performed on a DynaPro NanoStar 499DPN (Wyatt Institute®) at 
fixed 90° scattering angle. A 658 nm laser is used to illuminate the sample, and 10 
measurements with 5 seconds acquisition time for each measurement are obtained and 
averaged per sample. The hydrodynamic radius of the protein aggregates are estimated 
from the autocorrelation function and the relative amount of mass (%mass) at each radius 
is shown when plotting %mass against radius.  
 HSA was chosen as model protein molecule for this SERS and DLS experiment 
given its ubiquitous presence in human body fluids. Three HSA solutions are prepared in 
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three different solvent systems: water, PBS and 10% glycerol. Therefore the effects of 
ionic strength and viscosity, which are known to play an import role in protein 
aggregation formation,132,133 can be examined simultaneously by SERS and by DLS. 
Each solvent is double-filtered by a 0.22 micron syringe filter before protein solution 
preparation and the concentration of HSA is 1 mg/mL. The HSA solution is prepared by 
slowly adding 1mL of the solvent drop-wise to 1 mg lyophilized protein powder in a 2 
mL borosilicate glass container. Then the solution is left undisturbed for one hour at 
room temperature to allow thorough rehydration.  
 During the SERS and DLS experiments, a long gel-loading pipet tip (Corning®) 
is used to avoid bubbles during HSA solution preparation. Immediately preceding SERS 
and DLS measurements the glass container is gently inverted to ensure solution 
homogeneity. Extreme caution is taken to avoid any bubble formation during this 
inversion. 1 µL of the HSA solution is loaded onto a gold SERS substrate. Then 4 µL of 
the same HSA solution is added to a micro-cuvette (Wyatt Institute®) to perform the 
DLS measurement. Then the HSA solution is agitated by vigorous pipetting. The solution 
is left still for 5 minutes to allow the bubbles to float to the top, and using a long gel-
loading pipette tip 1 µL and 4 µL of the solution is obtained from the bottom of the 
container for SERS and DLS measurement respectively. To ensure the changes of %mass 
before and after agitation are not due to the presence of bubbles, DLS measurements are 
repeated on the same solution 15 minutes after agitation to confirm the result.  
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4.3 – Results and Discussion 
4.3.1 - SERS spectra of proteins on gold and silver substrates 
Five different proteins, apo-transferrin, avidin, HSA, insulin and ubiquitin, were 
studied by SERS. The Ribbon representation of their tertiary structures are shown in 
Figure 4-1. These five protein molecules are of different molecular weights and 
secondary structures which can be used to study the effect of size and shape, respectively, 
on the SERS spectral features. For example HSA (alpha-helical), avidin (beta-sheet) and 
transferrin (mix) are of similar size but have different secondary structures, while HSA 
and insulin have similar secondary structure but differ in size (see Figure 4-1). The effect 
of monomer vs multi-mer (avidin vs ubiquitin and HSA vs insulin) are also included in 
this protein group.  
 
Figure 4-1 Ribbon diagram representing the tertiary structures of five protein molecules 
studied by SERS. These five protein molecules has different tertiary and secondary structures, 
molecular weight, and number of amino acid residues.   
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However despite the difference in size and shape, Figure 4-2 shows the SERS 
spectra of these five proteins on the gold and the silver substrate exhibit very similar 
SERS spectral features. All of these proteins show the three characteristic broad spectral 
features on the gold substrate and narrow bands on the silver substrate. However, each 
protein molecule can still be distinguished from each other on both the gold and silver 
substrate resulting from the difference in relative band intensities. This figure shows that 
the size and shape of the protein does not cause dramatic differences on the SERS spectra. 
However, closer inspection of protein SERS spectra on gold substrates reveals that weak 
but recognizable narrow vibrational features can be seen after the three broad bands are 
removed through baseline correction as shown in Figure 4-3. The optimized baseline 
determine by msbackadj in comparing with the original SERS spectrum are shown in 
Figure 4-4. The most important point from this figure is that each protein shows a 
different signature on the baselined gold spectrum. However these same protein spectra 
on the silver substrates differ mainly by the relative intensity of the common vibrational 
bands. In addition, most of the silver spectral bands, such as the 936 cm-1, 1004 cm-1, 
1035 cm-1, 1385 cm-1, 1450 cm-1 and 1600 cm-1 are observed in the baselined gold 
substrate spectra and shared in all four proteins. The assignment for these silver bands 
has been given in Table 3-2. The contribution from the disulfide bond stretch (νS-S) from 
~500-550 cm-1 region104 are visible for each protein on the baselined gold spectrum but 
not visible on the silver spectra.  However, the ~615 cm-1 band which was assigned to C-
S stretch,102 is present in the gold baselined spectra of insulin and avidin but very weak in 
HSA and apo-transferrin.  
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In conclusion, all five studied proteins, regardless of size and shape, show similar 
SERS spectral features on gold and silver nanostructured substrates. However, weaker 
and narrower bands unique to each protein can be seen on the gold spectrum after the 
broad spectral features are removed. In addition, most of the silver spectral bands except 
the 615 cm-1 band are observed in the baselined gold spectrum. The molecular 
mechanism that causes the presence of the broad protein spectral features on the gold 
substrates is not evident for proteins on the silver substrate. Thus the silver spectrum of 
the protein is dramatically different from its corresponding SERS spectrum on gold. The 
observation of very similar SERS spectral features for all five protein molecules despite 
the large difference in size and shape of these molecules is surprising, given the well-
established ability of Raman spectroscopy to distinguish protein secondary and tertiary 
structures. Moreover, the three broad spectral bands on the gold substrate have not been 
previously reported for any of the five proteins studied here. The origin of these broad 
SERS spectral features and the mechanism of their formation on gold SERS spectrum 
will be discussed below. Since HSA is the most the abundant protein in humans, the 
studies described in the next two sections will focus on HSA.  
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Figure 4-2 SERS spectra of various protein molecule solutions in water on the gold substrate 
(left) and the silver substrate (right). On the gold substrate all protein molecules display three broad 
spectral features center around 1550 cm-1, 1200 cm-1 and 900 cm-1, but each protein can still be 
distinguish from each other from the relative intensity of the three broad features. On the silver 
substrate all protein display similar, narrower spectral bands but each protein can still be 
distinguished based on the difference in relative peak intensity.  
 
 
Figure 4-3 After removing the three broad spectral features by MATLAB function msbackadj 
distinct, narrower spectral features can be seen for each of the four protein molecules on the gold 
substrate. Each protein shows different gold spectral features, but many common bands can be 
found among them. Comparing with their silver SERS spectra (right) show that almost all silver 
spectral features (with exception to the ~610 cm-1 features) can be seen on the baseline gold spectra.  
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Figure 4-4 The optimized baseline determined by MATLAB function msbackadj is shown with 
the original spectrum.  
 
4.3.2 - Perturbing the SERS Protein Spectra 
Effects of ions and ionic strength 
 Ions have complex effects on the structural stability of proteins in solution. Ions 
can modulate the strength of electrostatic interactions by interacting with unpaired 
charged side chains on the protein surface, both within the protein and between protein 
molecules. Binding of multivalent ions can cross-link charged residues between two 
protein surfaces and leading to protein stabilization125,126 (salting-in effects), whereas 
intramolecular charge-charge interactions disrupt the conformational stability (salting-out 
effects).127 The net effect of salt on protein stability is thus a delicate equilibrium balance 
between intermolecular protein-salt-protein interactions and intramolecular protein-salt 
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interactions. The ability of ions to salt-out or salt-in proteins are classified by the 
Hofmeister series, first work out by Franz Hofmeister in 1827. He discovered a series of 
salts that had consistent solubility effects on chicken egg protein mixtures, which was 
extended to the stability of their secondary and tertiary structures in the salt solution as 
discovered later. The Hofmeister series ranks ions in the order of their ability to stabilize 
protein structure in aqueous solution.128 The Hofmeister series for cations is,  
NH4+ > K+ > Na+ > Li+ > Mg2+ > Ca2+ > guanidinium 
Anions usually have a larger impact on protein solubility than cations and the 
corresponding series is,  
F- ≈ SO42- > HPO42- > acetate > Cl- > NO3- > Br- > ClO3- > I- > ClO4- > SCN- 
Although some controversy about the mechanism of ion effects still persists, the 
Hofmeister series is commonly exploited in protein precipitation and purification 
procedures. For example the highest ranking cation and anion in the series (NH4)2SO4 is 
used extensively for bulk protein precipitation from a cellular lysate mixture. At 
sufficiently high salt concentrations the protein components precipitated out. By 
increasing ammonium sulfate concentration stepwise the precipitated protein components 
in the mixture is recovered between each step.    
 In this section, the effects of cations and anions as well as ion strength to the 
broad SERS spectral features on the gold substrate are described. Particularly, the 
perturbation of SERS spectra of HSA on gold by 100 µM of Na+, K+ cations and Cl-, 
NO3- anions are explored. All these ions are early members of the Hofmeister series and 
thus expected to destabilize the protein structure in solution. In addition to these four ions, 
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the effect of Ag+ (in the form of AgNO3) is studied on the gold substrate. As shown in 
Chapter 4, the same protein displays very different SERS spectral features on gold and 
silver nanostructured SERS substrates (Figure 4-2) and thus adding Ag+ ions to the 
protein may help to understand the origin of such sharp differences.  
 Figure 4-5 shows the SERS spectra of HSA in 100 µM of KCl, NaCl, NaNO3 and 
AgNO3 on the gold substrate. These are compared to the HSA SERS spectrum in pure 
water as a reference at the bottom of this figure. Except for HSA in AgNO3 which shows 
only a weak SERS spectrum with few bands, the HSA SERS spectra in the other three 
salt solutions display the three characteristic broad bands on the gold substrate. Also the 
differences between the HSA SERS spectrum in these three salts is relatively small and 
mostly due to differences in relative peak intensities.  For example, note the relative 
intensity of the 1150 cm-1 band in Figure 4-5. Thus, the broad spectral features on the 
gold substrate are largely not affected by protein size, shape or the presence of ionic 
species. Moreover, the broad SERS features of HSA on gold don’t seem to be affected by 
the concentration of salt as shown in Figure 4-6. Relatively few spectral changes are 
observed for the HSA SERS spectrum on gold as the NaCl concentration ranges from 1 
µM to 100 µM. However given that Na+, K+, Cl- and NO3- are earlier members of the 
Hofmeister series and thus tend to destabilize the protein structure in solution, one may 
conclude that the observed broad gold spectral features are related to the destabilized 
protein structure. One simple test of this hypothesis is to study the protein SERS spectral 
changes upon dilution.  Also comparing the dilution dependence of both the gold and 
silver SERS spectrum of the same protein may help to understand the mechanism that 
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causes the very different spectral features observed on these two substrates.   
 
Figure 4-5 SERS gold spectra of HSA in 100 µM salt solutions: silver nitrate (AgNO3), sodium 
chloride (NaCl), potassium chloride (KCl) and in water as reference. The three broad gold spectral 
features are observed in all the salts except in silver nitrate.  
 
Figure 4-6 SERS gold spectra of HSA in NaCl of different concentration to study the effect of 
ion strength to the three spectral features. SERS spectra of HSA in water is shown at the bottom.  
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The effect of protein concentration on SERS gold and silver spectral features 
 
Figure 4-7 Dilution of HSA and avidin, two protein molecules of similar size but having alpha-
helix and beta-sheet respectively, as main secondary structure on the gold SERS substrate. The three 
broad spectral features intensity decrease with dilution in water.  
 
 
Figure 4-8 Dilution of HSA and avidin in water on the silver SERS substrate. The intensity and 
the S/N ratio of the SERS spectral features of both protein molecules on the silver substrate increase 
with dilution.  
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Figure 4-7  shows the dilutions of the aqueous solutions of HSA and avidin, two 
protein molecules of similar sizes but different secondary structures, on the gold substrate. 
The three broad spectral features are evident for both proteins. What’s more important is 
that there are few changes of the relative peak intensities and narrow, fine spectral feature 
on the broad spectral features as a function of dilution. In other words, dilution only 
causes the decrease of overall spectral intensity due to the lower molecular concentration, 
but the chemical species that cause the three broad spectral features remain intact during 
dilution.  A good hypothesis of such chemical species is protein aggregates in the 
solution created during the solution preparation process, since the protein structural 
changes during aggregation formation are both irreversible and thermodynamically 
stable.129  Therefore if protein aggregation is the cause of the broad spectral features, 
dilution will not cause major structural change on these aggregation and will only result 
in decrease of the overall signal intensity. 130 
Furthermore, Figure 4-8 shows that the dilution of HSA and avidin display 
different behaviors on the silver substrate compare to the gold substrate. The three broad 
spectral features disappear on the silver substrate and the narrower bands attributed to 
amino acid residues (Table 3-2) appear. Interestingly, the intensity and signal-to-noise 
ratio of these narrow bands increase with dilution. The appearance of spectral features 
from individual amino acid is attributed to the known strong interactions of the silver 
nanoparticles with the protein molecules.131, 132, 133, 134  Treuel et al. demonstrated via 
SERS that there are strong interaction between sulfur-containing groups (serine, cysteine 
and methionine) in bovine serum album (BSA) and uncoated silver nanoparticle.135 This 
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is consistent with our protein silver SERS spectrum on Figure 4-8. The ~ 615 cm-1 band 
which is assigned to C-S stretch becomes evident for avidin at lower concentration. In the 
same study135 it’s also shown via circular dichroism that BSA loses its α-helix features 
when interacting with the silver nanoparticles. In other words, silver nanoparticles have 
the ability to denature protein molecules. These silver nanoparticles-protein interactions 
are the cause of the cytotoxicity of silver nanoparticles in vivo and have been known and 
exploited as an antimicrobial agent. For example, silver staining is a common technique 
to visualize the protein bands on polyacrylamide gel after electrophoresis, and an aqueous 
solution of 1% silver nitrate is used to prevent bacterial conjunctivitis in newborn babies. 
Based on these observation, we attribute the dramatically different spectral features of the 
same protein on gold and silver substrates are due to the strong interactions between the 
protein and the silver nanoparticles which disrupt the aggregated protein molecules and 
allow the observation of features from individual amino acids on the silver substrate. The 
reason why the silver SERS signal intensity increases upon dilution is because dilution 
lowers the ratio between protein aggregates and silver nanoparticles, i.e. more silver 
nanoparticles are available to interact on a per aggregate basis, resulting in better SERS 
signals on the silver substrate upon dilution.  
This dilution experiment suggests that protein aggregates may be the chemical 
species that cause the broad spectral features observed on the gold substrate. Also 
discussed in this section, the reason for the difference between the gold and the silver 
protein spectral features is attributed to the more perturbative nature of the silver 
nanoparticles. However, additional evidence is needed to confirm the presence of protein 
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aggregation as well as understand how the aggregates are form. In the next section, 
dynamic light scattering (DLS) in conjunction with our SERS measurements will be 
described in the next section to confirm the presence of aggregates. The comparison 
between the SERS and DLS results will not only allow the understanding of the unique 
gold SERS spectral features but also adds SERS to the list of rapid, ease-to-use optical 
technique for protein aggregates studies.  
 
4.3.3 - Origin of the Protein SERS Signature 
In this section the results from dynamic light scattering (DLS) will be compared in 
conjunction with the gold SERS spectrum of HSA to confirm the hypothesis that the 
three broad spectral bands observed on the SERS spectrum are caused by protein 
aggregates in the solution. The question of how these protein aggregates are formed in 
the solution will also be addressed. Three solvent systems are chosen to be studied by 
SERS and by DLS: water, PBS and 10% glycerol. Thus the effects of ionic strength125, 126 
and viscosity136 which are known to play important roles in protein aggregation formation 
will be studied simultaneously by SERS and by DLS.  
DLS is a powerful technique to determine the size distribution of small particles 
suspended in solution. DLS measures the intensity fluctuation of scattered light resulting 
from the Brownian motion of small particles (<250 nm) in solution. Since the distances 
between molecules in solution are constantly changing, the scattered light from one 
molecule can undergoes either constructive or destructive interference with the scattered 
light from its neighboring molecule and information can be obtained about the time scale 
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of movement of the scatters. The dynamic information of the particles is derived from an 
autocorrelation of the changing intensity recorded in the experiment. An exponential 
decay of the autocorrelation function will thus indicate the particle is in motion, and the 
rate of motion is related its diffusion coefficient. Since the diffusion coefficient is 
inversely related to the radius for small spherical particles, the autocorrelation function 
will thus provide an estimation of the hydrodynamic radius of the molecule, or the radius 
of an equivalent hard sphere diffusing at the same rate as the molecule under observation, 
in solution.  
 Protein aggregation can be induced by a wide variety of conditions, such as 
temperature, pH, freezing and/or thawing and mechanical stress such stirring, pipetting 
and shaking.98,99 Since in our previous SERS protein experiments the solutions are 
prepared at constant temperature and our efforts with varying salt and ionic strength of 
the solution doesn’t cause significant change of the gold SERS spectral features of the 
protein, this experiment will focus on the effect of mechanical stress on the induction of 
protein aggregation.  
The shearing stress during agitation, such as stirring, pipetting and shaking, are 
known to induce protein aggregation.98, 137 In addition, agitation can cause cavitation, or 
the formation of voids or bubbles within the protein solution which rapidly collapse and 
sends shock waves that can perturb the tertiary structure of the protein.138  HSA solutions 
were initially prepared at 1 mg/mL concentrations as gently as possible to minimize 
aggregation formation.  Then aggregates are induced by vigorous pipetting to generate 
both shearing stress and cavitation. Simultaneous comparison of the SERS and DLS 
 81 
measurement before and after pipetting confirms our previous hypothesis that the protein 
SERS spectral features on gold are caused by protein aggregation in the solution (See 
Figure 4-9). This is evidenced by the increase in % mass of particles with larger radius 
after agitation which is coincident with the increase of the overall signal SERS intensity. 
The magnitude of increase in % mass for larger particles is roughly correlated to the 
increase in SERS signal intensity, with 10% glycerol shows the greatest increase. In 
addition, narrower bands such as the ~1000 cm-1 and ~1030 cm-1 begin to appear on the 
SERS spectra for the un-perturbed protein solution. This observation is in agreement with 
results shown in Figure 4-3 that after the broad spectral features are removed the 
contribution from individual amino acid residues appear.  
From these SERS and DLS experiments the molecular origin of the broad protein 
SERS on gold spectral features that are observed for all proteins we have studied are 
established to result from protein aggregation, which is probably created by agitation 
during the protein solution preparation process. We note that these protein aggregates are 
not affected by the presence of ions or ionic strength (Figure 4-5 and Figure 4-6) with the 
exception of silver nitrate. This is probably because silver ions can bind to and interact 
strongly with the protein aggregates thus allowing the appearance of vibrational features 
from individual amino acid residues to appear in the SERS spectrum.  
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Figure 4-9 Simultaneous comparisons between SERS (bottom) and DLS (top) measurements of 
HSA solution in three solvent systems before and after agitation confirm the molecular origin of the 
three broad spectral features on the gold SERS spectrum of HSA as protein aggregation in the 
solutions.  
 
4.4  - Conclusion  
The results demonstrated in this chapter shows that protein aggregation can be 
observed by our SERS method. Previous literature reports of proteins SERS studies have 
been focused on the observation and identification of features from individual amino acid 
residues by utilizing the strong interaction between the protein molecules and silver 
nanoparticles. Few previous protein SERS studies reports have employed gold 
nanoparticles and, as far as we are aware of, the ubiquitous characteristic broad protein 
aggregation gold spectral features we observe have not been reported in prior studies. 
Since protein aggregation has significant impacts in many areas such as in understanding 
disease progression in Alzheimer’s and Parkinson’s Diseases, and in therapeutic 
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development where the stability of a protein drug is paramount to patient safety and 
treatment efficacy, the ability of SERS to observe characteristic signatures of protein 
aggregations offers a new and powerful bioanalytical probe. More importantly, since it 
has been shown that the SERS vibrational signature of protein aggregates are universal 
regardless of the size and the secondary and tertiary structure of the protein, ionic 
strength and solution viscosity, SERS would be a valuable and ease-to-use tool for 
identifying the presence of protein aggregates under complex conditions such as those in 
body fluids and during disease progression. An essential remaining question is how does 
protein aggregation result in the three broad vibrational features observed on gold 
substrates. Understanding the underlying molecular origins of this robust protein 
aggregate structure will be of great value because it will reveal the mechanism of protein 
aggregation and such knowledge may help understanding protein-misfolding more 
generally especially in the context of human diseases.  
 
5. SERS Diagnostic Platform: Cancer Cell Detection 
5.1  - Basis of Metabolomic-based Cancer Identification 
Cancer is responsible for nearly 1 in 6 death globally in 2015 and an increase of 70% 
new cases is expected in the next two decades.139 For all cancer types, early diagnosis is 
crucial for effective treatment, higher survival rate and improved quality of life. 
Therefore screening tests to identify cancer cells are paramount for early diagnosis of 
cancer. Given that cancer is a highly complex disease and screening tests are to be 
applied to a large population, such tests must be cost-effective, multiplexing, ease-to-use, 
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sensitive and specific.139, 140   
Metabolomics or the analysis of the complete metabolites from a cell, organ or 
organism focus on quantifying the concentrations of low-molecular weight metabolite 
molecules that can be detected by various analytical methods.141 Metabolomics analysis 
is particularly useful for identifying biochemical pathways that are perturbed in a 
particular pathological process, such as tumorigenesis.142 Metabolomic analysis has been 
successfully employed in the field of cancer biology.141 Cell metabolism is known to be 
altered in tumor cells. The first tumor-specific metabolic alternation was reported in 
1930s by Warburg, who demonstrated that cancer cells rely on an increased dependence 
on glycolysis, a metabolic pathway normally used by anaerobic organisms for ATP 
generation, even in the presence of sufficient oxygen. 143,144 This switch from oxidative 
phosphorylation to glycolysis has been considered as a main hallmark of a cancer cell. 143, 
145  Other biological capabilities acquired during tumorigenesis process have been 
discovered and attributed as indicators for cancer as described by Weinberg et al.142 
including sustained growth signaling, evaded growth suppressor, resistance to aptosis, 
replicative immortality, angiogenesis and activated invasion and metastasis. Mutations 
occur during tumorigenesis at the “upstream” genomics and proteomics, i.e., genetic or 
enzymatic activity/concentration changes, are reflected in the “downstream” change in 
cellular metabolism. However, measurements of the change in the overall metabolite 
concentration is a much more sensitive approach than measuring the change in gene 
expression or enzymatic activity/concentration, because changes in the metabolic flux 
(the rate of change of total amount of material passes through a given metabolic pathway) 
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have a significant impact on the overall metabolite concentrations.146 
 
5.2  - Current Analytical Techniques for Cancer Metabolomic Study 
and Introduction of SERS-based Cancer Identification 
Metabolomics analysis of cancer cells is a powerful approach to identify 
biomarkers to use for diagnostics, treatment efficacy evaluation and identification of 
novel therapeutic targets.141,147 Currently nuclear magnetic resonance (NMR) and mass 
spectrometry (MS) are the two dominant experimental methodologies for this purpose. 
Examples of metabolic biomarkers of tumors identified by NMR or MS approaches 
include alanine, 148  saturated lipids,149  glycine,150  lactate,151  and nucleotides. 152  NMR, 
particularly MRI, is used extensively for metabolomic study in intact human tissues.153 
The non-invasive nature of NMR is valuable for in vivo monitoring of tumor progression. 
However, the disadvantage of NMR-based approaches is that only limited types of 
molecules can be identified in a simple one-dimensional spectrum. Co-resonance 
between two metabolite molecules can make quantification of metabolite concentrations 
difficult as well.141 On the other hand, MS-based approaches are used extensively for a 
full-spectrum proteomic and metabolomics analyses with good sensitivity.141 MS-based 
approaches can be further classified based on the sample separation method (GC-MS, 
LC-MS, HPLC-MS, etc.) and the type of ionization used (ESI, MALDI-TOF, etc.).148 
The metabolites are separated at the initial chromatographic stage first and then separated 
based on their mass to charge (m/z) ratio. MS-based approaches are far more sensitive 
than NMR-based approaches and more metabolite molecules can be identified from a 
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single measurement. However, the major problem is that not all metabolites can be 
readily ionized which potentially bias the metabolite identification result and limit the 
ability for quantitative measurements. Moreover, the presence of ions in the sample 
significantly impacts the ionization process and this problem is particularly prominent 
when the metabolite concentration in the sample is low.150 Additional treatment is 
required to remove ion sources from the sample, which usually involves extensive 
dialysis or solid-phase extraction. Finally, the hardware requirement and the high 
maintenance expense makes MS-based approaches less affordable to be used in a large 
scale in clinical settings.  
The advantages of SERS as rapid, label-free, sensitive and specific approach for 
disease diagnosis has been described in details in the previous chapters. The use of a 
SERS-based methodology for detection and identification of cancer has been investigated 
particularly over the last decade.154, 155, 156, 157, 158, 159, 160 The attributes of speed, ease-of-
use, sensitivity and specificity makes SERS an attractive analytical approach that could 
be used for real-time cancer diagnostics. Most of the previous SERS-based approaches 
for cancer identification center on the use of antibody-labeled metal nanoparticles that 
bind to cancer cell surface biomarkers and subsequently allow specific cellular imaging 
due to the bright SERS reporter molecules. The advantages of this approach are the high 
sensitivity and specificity associated with the selectivity of the antibody. However, this 
imaging approach is dependent on the identification of unique antigens that are over-
expressed on the cancer cell surface and the successful production of antibody-
conjugated nanoparticles with SERS reporter molecules. Alternatively, SERS spectra of 
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in vitro cultured cancer cell or blood plasma from cancer patient have been examined and 
shown to offer vibrational signatures that, when couple with multivariate data analysis 
techniques, can distinguish cancer and normal cells. 161, 162, 163, 164  In these reports the 
identities of molecules contributed to the SERS vibrational feature that allows the 
distinction between cancer and normal cells are assigned to anomalous cell surface 
features or alternated level of nucleic acids, proteins, saccharides  or lipids in the blood 
plasma. It’s interesting to note that in most of these studies a vibrational band of 
anomalous intensity around ~725 cm-1, which is attributed to adenine or to the C-N bond 
of quaternary ammonium groups in the membrane lipid bilayer components,161,162,163,164 is 
reported.  
 In this early stage of expanding the SERS methodology as a label-free cancer cell 
detection and identification diagnostic platform, this work will demonstrate, at least 
phenomenologically, the ability of SERS to distinguish in vitro grown non-tumorigenic 
and cancer cells based on their unique SERS vibrational signatures as well as their time-
dependent spectral dependence that can be used as an additional characteristic to identify 
cancer cells. We will also identify the main molecules contributing to these spectra which 
give rise to the ability to distinguish cancer and non-tumorigenic cells via SERS, as well 
try to understand the biochemical origins of these SERS molecular contributors.  
 
5.3  - Materials and Methods 
SERS active substrate   The SERS substrates used in this study are the gold SERS 
active substrate synthesized in our laboratories and described in details in the previous 
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chapters. 1 µL cell samples in Dulbecco’s phosphate buffered saline (DPBS, Life 
Technologies®) is added to the substrate and air-dried before spectral acquisition. 
Cancer/non-tumorigenic cell lines  Two epithelial cell lines, MCF10A (M1) and 
MCF10ACA1h (M3) representing non-tumorigenic mammary gland cells and invasive 
breast cancer cells respectively, are generously provided by Dr. Douglas Faller at the 
Evans Center for Interdisciplinary Biomedical Research at Boston University School of 
Medicine (BUSM). The M1/M3 combination is a breast cancer cell line model system for 
studying the mechanism of aberrant epigenetic DNA methylation pattern. 165  The 
advantage of using the M1/M3 cell system to demonstrate the ability of the SERS cancer 
diagnostic platform is both cell lines were derived from a common genetic background 
(MCF10A) and the genetic/epigenetic alternation on M3 compare to M1 is a good 
representation of the gradual progression from non-tumorigenic to carcinogenic state in 
vivo. In addition, both M1 and M3 cells will be cultured using the same growth medium 
formulation, therefore the possibility of observed SERS vibrational signature difference 
due to two cell lines being cultured in different growth media is eliminated.  
The general procedure for cell culture is summarized in Section 8.5 while details 
regarding specific cell lines are discussed below. All cell lines are grown in triplicate in a 
humidified 37 °C incubator with 5% CO2 by adhering to the surface of a TTP® tissue 
culture flask (T25, Corning®). The surface area is 25 cm-2 which corresponds to ~105 
cells/mL as determined by cell counting with hemocytometer at ~90% confluence (i.e.  
90% area of the flask surface are covered by cell monolayer), and the working volume 
(i.e. the volume of growth medium to be added to a cell monolayer) for the T25 flask is 5 
 89 
mL. Cell growth was monitored daily via an inverted microscope and the growth medium 
was refreshed every two to three days. Only cells after at least two passages were used in 
these experiment to ensure robustness.  
Specific cell culture instruction for M1 and M3 cells 
Reagent: both M1 and M3 cells are grown with the same reagent with the following 
composition. DMEM-F12, Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12. 
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.  DDwater, sterilized and 
double-filtered water by 0.22 micron syringe filter.  
Medium Final concentration Stock concentration 
Vol needed  
for 100 mL 
medium 
DMEM-F12 medium (Life 
Technologies®, with HEPES)   95 mL 
Filter the below items together, then add to DMEM-F12 
Heat-inactivated horse 
(equine) serum (ATCC®)  5%   5 mL 
Cholera Toxin (Fisher®, 1 
mg) 100 ng/mL 
1 mg/mL 
(Add 1 mL Ddwater) 
store at -20 °C, 10 
µL/tube 
10 µL 
Epithelial growth factor (Life 
Technologies®, 100 µg)  20 ng/mL 
50 µg/mL 
(Add 2 mL Ddwater) 
store at -20 °C, 40 
µL/tube 
40 µL 
Hydrocortisone (Sigma®, 
powder) 0.5 µg/mL 
500 µg/mL 
(measure 10 mg + 1 mL 
100% ethanol + 19 mL 
DMEM-F12) store at – 
20 °C, 100 µL/tube 
100 µL 
Insulin solution (Sigma®, 10 
mg/mL) 10 ng/mL 
10 mg/mL 
(Store at 4 °C, 100 
µL/tube) 
100 µL 
Harvest Time: 72 hours for M1 cell, 48 hours for M3 cell.  
 90 
Sample Handling Each of the three T25 flasks was harvested individually using 
trypsin-EDTA following the procedure described in Section 8.5. The harvested cells are 
spun down at 1000g for 5 minutes before transferring the cell pellet to a 2.0 mL micro-
centrifuge tube. Cells in each micro-centrifuge tube are washed four time with 1 mL of 
DPBS at room temperature. After the last wash, all supernatant is removed and 5-10 µL 
DPBS is added to the tube without disturbing the cell pellet. The cells are left at room 
temperature and SERS spectra are acquired as a function of time post washing.  
SERS spectrum acquisition and Data processing   All SERS spectra are 
acquired with an RM-2000 Renishaw® Raman microscope employing a 50x (infinity-
corrected, 0.75 numerical aperture) objective and 785 nm excitation. Incident laser 
powers of ~ 0.45 mw and ~10 seconds of illumination time are used to obtain the 
reported bacterial SERS spectra.  The illuminated Raman excitation field of view is ~30 
µm x 2.5 µm. Ten SERS spectra per culture flask are acquired and data from all three 
flasks (30 spectra) are inspected to ensure robustness within the same flask and 
reproducibility between different flasks. Then the ten spectra with highest S/N ratio are 
selected and averaged. The averaged spectrum is baseline corrected and plotted in a 
spectral region from 400 – 1800 cm-1 with MATLAB®. 
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5.4  - Results and Discussions 
Time-dependent SERS spectral feature change is the key to distinguish non-
tumorigenic and cancer cells 
The SERS spectra as a function of time post-washing for non-tumorigenic 
mammary gland epithelial cell (M1, red) and for invasive breast cancer cells (M3, blue) 
are shown in Figure 5-1. The M1 and the M3 cells can be distinguished immediately after 
washing (t = 0 min) in which the M1 cells shows broad and weak spectral features that 
resembles an aggregated protein spectrum (Chapter 4), but the M3 cells shows narrower 
bands such as the 736 cm-1, 965 cm-1 and 1030 cm-1. Within 30 minutes the M1 cells 
begin to show stronger SERS signal and very distinct vibrational bands with the most 
intense band centered around 735 cm-1. However, a notable time-dependent red-shift of 
this band from 733 cm-1 to 725 cm-1 are observed on the M1 cells after 30 minutes. This 
red-shift from 735 cm-1 to 725 cm-1 is accompanied by a slight decrease of the overall 
intensity. On the contrary the M3 cells show no such red-shift of its most intense band as 
demonstrated in the zoom-on view on the right, and the overall intensity increases with 
time. Also SERS signals intensities from the M3 cells are considerably stronger than the 
M1 cells after 30 minutes as evidenced from the signal-to-noise ratio. Both cells show a 
decrease of the 1030 cm-1 band intensity after ~60 minutes.  These vibrational bands have 
been previously reported in our bacteria SERS spectra (Chapter 2 and Chapter 3) and 
have been assigned to features from purine metabolites. The 1030 cm-1 band has been 
determined to be due to nicotinamide adenine dinucleotide as described on our N. 
gonorrhoeae spectrum (Figure 3-4). As discussed in Chapter 3 since the oxidized and 
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reduced form of nicotinamide adenine dinucleotide can’t be distinguished from their 
SERS spectra, we will denoted as NAD/NADH.  
 To determine the relative contribution of each molecular components to the M1 
and M3 spectra we will use the best-fit method discussed in Chapter 2. The best fits are 
shown in Figure 5-2 and the contributions are shown as bar graph on the top. Almost all 
spectral features in each spectrum are captured by its best-fit with minor difference in 
relative intensity. It’s evident from the bar graph that the red-shift of the ~733 cm-1 to 
~725 cm-1 band on the M1 cell spectra corresponds to the change of ATP to 
hypoxanthine as the largest molecular contributor to the SERS spectrum. On the other 
hand, the contribution of each molecular component to the M3 SERS spectra remain 
relatively constant throughout the experiment, with adenine and ATP making the largest 
and second largest contribution to each spectrum. Hence no time-dependent shift of the 
most intense band is observed on the M3 spectra. We noted that the consistent 
discrepancy between the M3 experimental spectra and best-fits of the 735-to-965 cm-1 
band ratio, and this discrepancy has been attributed to the local acidic pH environment 
near the cell surface (See   The contribution from NAD/NADH decreases with time in 
both cell lines as evidenced by the decreasing intensity of the 1030 cm-1 band.  
 93 
 
Figure 5-1  Side-by-side comparison of the SERS spectra of non-tumorigenic M1 cells (red) and 
invasive breast cancer cell M3 (blue) as function of time post-washing. The time-dependent red-shift 
of the 733 cm-1 band on M1 cells is contrasted with the M3 cells which show no red-shift in the zoom-
in view on the right.  
 
 
Figure 5-2 Best fits (black) resulting from linear combination of SERS spectra of four purines, 
NAD/NADH and protein for M1 and M3 cells at each time point are shown. The relative 
contributions of each molecular components are shown as bar graph on the top.  
 
 94 
 Although a larger database of cancer/normal cell combinations is needed to 
confirm the generality of this dynamical SERS effect, Figure 5-1 and Figure 5-2 
demonstrate the new possibility of using a SERS platform to distinguish non-tumorigenic 
and cancer cells. From the data presented in Figure 5-1 it can be seen that two key SERS 
phenomena are the basis for distinction between non-tumorigenic and cancer cells. The 
first is that non-tumorigenic cells exhibit weak and broad spectrum which resemble 
features from protein aggregations (Chapter 4) initially after washing while the cancer 
cells always show relatively stronger and narrower spectral features. The second is that 
non-tumorigenic cells exhibit a time-dependent red-shift of the most intense band from 
centered on ~733 cm-1 to ~725 cm-1 while the cancer cells don’t exhibit such time-
dependent shifts. This red-shift corresponds to a change of ATP to hypoxanthine as the 
largest contributor to the SERS spectra. This time-dependent change occurs within 60 
minutes post sample washing.  Thus, monitoring SERS spectra of cells isolated from a 
biopsy sample for up to one hour after washing SERS can provide evidence of a 
distinction between cancer and normal cells without the need for antibody labeling.  
 In the next section, the possible biochemical origin of the presence of these purine 
metabolites is discussed. Specifically, the appearance of these purine metabolites as well 
as the observed time-dependent spectral change is related to the known purinergic 
signaling cascade that occurs at near-cell membrane extracellular region.  
Extracellular purine molecules are purinergic signaling molecules  
 The action of purine and purine nucleosides/nucleotides as extracellular signaling 
molecules has long been recognized and appreciated. Burnstock et al. first described the 
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release of extracellular ATP as transmitter between non-adrenergic inhibitory nerves.166 
Burnstock’s hypothesis was initially met with skepticism primarily because as the key 
energy source molecule, it seem unlikely for such important molecule to be present 
extracellularly for cell signaling purpose. Nevertheless, three decades later, following 
cloning and characterization of the ATP receptors expressed on cell membrane, 
purinergic signaling has been a well-established concept and has been applied to cancer 
research as well.167 The role of extracellular ATP and adenosine, and purinergic signaling 
cascade in tumorigenesis progress has been extensively studied.168, 169, 170 Purines can be 
released by any cell types to the extracellular region,171  but the concentration of 
extracellular purines increase dramatically from nano-and pico-molar to micro-molar 
level when cells are under stress condition such as damage, inflammation, hypoxic and 
apoptosis.172, 173, 174  Thus it seems possible for the presence of extracellular purine 
molecules at concentrations detectable by SERS when the cells are placed in a nutrient-
depleted environment which pose immense stress to the cells. Figure 5-3 summarized the 
typical routes of ATP release to near-cell membrane extracellular regions.  
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Figure 5-3 Summary of the non-lytic mechanism for release of ATP to extracellular region. 175 
Since ATP and adenosine are powerful cell growth stimuli, their activity and extracellular 
concentrations are regulated by a series of ecto-nucleotidase on the cell outer membrane 
by either directing the import of these two molecules back to the cytoplasm or by 
subsequent conversion to purine bases such as hypoxanthine. 175   The inactivation 
mechanism of purinergic signaling cascade by the actions of ecto-nucleotidase is 
illustrated in Figure 5-4. Thus it seems possible that time-dependent ATP-to-
hypoxanthine shift observed on the non-tumorigenic M1 cell (Figure 5-2) reflect this 
normal inactivation process when ATP are converted to hypoxanthine and subsequently 
xanthine. Furthermore, it can be anticipated that in cancer cells this inactivation 
mechanism is mutated or non-functioning,168, 169, 170 therefore the M3 cells are able to 
maintain relatively constant extracellular [ATP] concentration as evident from the bar 
graph on Figure 5-2. Hence the M3 cells can sustain constant growth signaling, one of the 
six hallmarks of cancer as described by Weinberg.142  
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Figure 5-4 The inactivation mechanism of ATP purinergic signaling cascade by membrane-
bound nucleotide converting-ectoenzymes.175  
 
5.5  - Conclusion and Future work 
The results described in this chapter demonstrates the ability of the SERS platform 
to distinguish in vitro grown cancer and normal cell lines as well as the potential of SERS 
as novel bioanalytical probe for studying the purinergic signaling processes occurring at 
near cell membrane extracellular region. Two cell lines, non-tumorigenic mammary 
gland epithelial (M1) cells and invasive breast cancer (M3) cells, are studied using the 
gold substrate. These cells show similar spectral features as the bacterial spectra reported 
previously in our laboratories, and the main molecular contributor to the SERS spectra of 
these cell lines are found to be four purines, adenine, ATP hypoxanthine, and xanthine, 
and nicotinamide adenine dinucleotide (NAD/NADH). However several distinct SERS 
characteristics are found to be unique to these non-tumorigenic/cancer cells. These 
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includes the presence of the ~1030 cm-1 band which is associated with the presence of 
NAD/NADH known to be elevated in cancer cells176 and had only been previously 
observed on the fastidious bacterial species N. gonorrhoeae, and the decreasing 
contribution of NAD/NADH as a function of time post-washing. The most unique SERS 
characteristic to these normal/cancer cell lines are the red-shift of the most intense band 
from ~733 cm-1 to ~725 cm-1 which had not been observed previously in any of our 
bacterial SERS spectra or reported in the literature. This red-shift is due to the change of 
ATP to hypoxanthine as the largest SERS molecular contributor as a function of time 
post-washing. This time-dependent change is related to the conversion of ATP to 
hypoxanthine by the action of a series membrane-bound nucleotide converting-
ectoenzymes. Moreover, this ATP-to-hypoxanthine time-dependent change is the most 
important SERS characteristic to distinguish non-tumorigenic M1 cells and cancerous M3 
cells. The M1 cells display this ATP-to-hypoxanthine time-dependent change within 60 
minutes post washing while the M3 cells don’t show such a time-dependent change. By 
monitoring the SERS spectra of a sample for up to one hour after washing our SERS 
platform could provide a distinction between the M1 and M3 cells. The biochemical 
origin of these purine molecules is proposed to result from the molecules involved in 
extracellular cell signaling pathways. The purinergic signaling cascade is activated in 
cells are under stressful condition, and by placing the cells in a nutrient-depleted 
environment the cascade is activated and the concentration of extracellular purines 
increase dramatically. Since purine molecules especially ATP and adenosine are potent 
growth factor, their concentrations are regulated by series of ecto-nucleotidase on cell 
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membrane which can inactivate them by converting them to hypoxanthine and 
subsequently other free purine bases. Therefore it’s possible the time-dependent ATP-to-
hypoxanthine change observed on the SERS spectra of the M1 cells reflects this 
inactivation process, while in M3 cells the inactivation mechanism of the purinergic 
signaling cascade is defected or non-functioning and thus no such time-dependent change 
is observed. The results in this chapter demonstrate at least phenomenologically the 
ability of SERS to detect and identify in vitro grown cancer cells as well as the potential 
of the SERS platform for studying cancer metabolomics.  
 
6. Conclusion 
The results described here demonstrate the potential of SERS of living cells as a 
molecular disease diagnostic platform and as a probe for studying metabolomic activities 
that take place at near-cell extracellular region. When compounded with appropriate 
sample preparation and enrichment procedure, multivariate classification model for 
unknown prediction and portable instrument, SERS could provide rapid (<1 hour), 
sensitive and specific diagnostic of bacterial infections in body fluid and cancer cell 
identification without the requirement for the slow cell growth step. The basis of the use 
of SERS for rapid diagnostic is the multiplexing capability which allows simultaneous 
identification of different purine metabolites from the same spectrum. With the exception 
of C. trachcomatis in which aggregated proteins are found to be key contributor to their 
SERS spectra, purine metabolites release to extracellular regions by the bacteria as 
response to starvation are the key SERS biomarker and serve as basis for strain 
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identification in unknown sample. In cancer cells, these purine are found to be release by 
the cells to extracellular as part of purinergic signaling cascade.  The spectral differences 
on the gold and the silver SERS substrate of the same molecules as well as the time-
dependent changes provides additional basis for bacteria and cancer cell identification. 
The ability of SERS to observe protein aggregates extends the applicability of SERS 
platform beyond disease diagnostics as a novel, powerful bioanalytical probe for the 
dynamic of protein structure in solution, which may be of value in protein therapeutic 
research for both safety and treatment efficacy reasons.   
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7. Supplementary Figures and Information  
7.1 – SERS Diagnostic Platform: Urinary Tract Infection  
 
a Escherichia coli (E. coli), Klebsiella pneumoniae (K. pneu) 
bS = susceptible, R = resistant 
Table S-7-1 Gram-negative UTI Clinical Isolates a,b  
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a Staphylococcus saprophyticus (S. sapro), Enterococcus faecalis (E. faecalis) 
bS = susceptible, R = resistant, I = indeterminate 
Table S-7-2 Gram-positive Clinical Isolates a, b 
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Table S-7-3 PLS-DA classification confusion table results for the cross validation model 
treatment of the SERS spectra of 12 UTI causative clinical isolates. 
 
 
Table S-7-4 PLS-DA classification sensitivity and specificity for twelve UTI bacteria SERS 
spectra. 
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ad = adenine, hx = hypoxanthine, xan = xanthine, gu = guanine, ua = uric acid, AMP, gs 
= guanosine 
Table S-7-5 Relative contribution of purine components to UTI bacteria SERS spectra 
 
 
Figure S-7-1  Plot of the PLS-DA classification cross validation root mean square error 
(RMSECV) as a function of the number of latent variables (LV) selected.  24 LVs was selected for 
this treatment because this number corresponded to a minimum in the RMSECV. 
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7.2  - SERS Diagnostic Platform: Sexually Transmitted Disease 
 
Figure S-7-2           Sensitivity of C. trachomatis (Ct) on gold and silver SERS substrate at t = 0 min 
(right after sample processing). The initial concentration of elementary body is determined by titer to 
be ~105 ifu/mL. The lowest concentration of EB to yield SERS signal on gold is determined to be 
~5x104 ifu/mL and ~102 ifu/mL on silver.  
 
 
Figure S-7-3 Sensitivity of N. gonorrhoeae (Ng) on gold and silver SERS substrate at t = 60 
minutes post sample processing. The initial concentration of Ng is determined by serial dilution and 
overnight cell culture to be ~ 107 cfu/mL. The lowest concentration of bacterial cell to yield SERS 
signal is ~ 106 cfu/mL on both metals.    
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Figure S-7-4 Gold and silver SERS spectra comparing the signal from C. trachomatis cell and 
from the unfiltered supernatant fluid around the cell as a function of time post sample processing. 
On both metals the SERS molecular contributors are always found on the cell, hinting the identity of 
the SERS molecular contributors to be of cell membrane components.  
 
7.3  - SERS Diagnostic Platform: Cancer Cell Detection 
 
Figure S-7-5 SERS spectral features are strongly affected by the local pH environment on the M3 
cells. Comparing the best-fits calculated using adenine in DPBS (pH 7.0 – 7.6) vs adenine at acidic pH 
as compared to the experimental data for the M3 60 minutes and 180 minutes spectra show 
improvements on the 735-to-965 cm-1 ratio as well as the features from 1300-1400 cm-1 region.  
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Table S-7-6 Relative contribution of molecular components to M1 and M3 SERS spectra at each 
time point. 
 
7.4 -  Modeling compound SERS spectra 
In water 
  
Figure S-7-6  Normalized SERS spectra on gold substrate for seven purine compounds found 
contributing to the twelve UTI bacterial spectra. The vertical dash line correspond to a unique peak 
in the SERS spectrum of each purine that help to identify this molecular contribution to the bacterial 
SERS spectrum.  
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Figure S-7-7 Normalized SERS gold (red) and silver (blue) spectra of the three purine molecules 
found to be the components of the SERS spectra of N. gonorrhoeae.  
 
 
Figure S-7-8 The absolute intensity of adenine, NAD/NADH and guanine found in N. 
gonorrhoeae spectra are shown here on the gold and the silver substrate.  
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In DPBS 
 
Figure S-7-9 Normalized (left) and baselined (right) SERS spectra on gold substrate of molecular 
components (four purines, protein and NAD/NADH) found contributing to the SERS spectra of M1 
and M3 cells.  
 
8. Appendix 
8.1  - General laboratory cultivation guideline for vegetative bacteria 
Agar medium most bacteria can be cultured easily on trypticase soy agar, nutrient 
agar, or LB agar from frozen culture. It’s recommended the agar medium to be prepared 
according to manufacture instruction fresh before bacterial culture and stored at 4 °C for 
no more than one week. The bacteria should be plated and allowed to grow on the agar 
plate overnight at 37 °C. 
Broth medium common broth media for bacterial culture include trypticase soy 
broth (TSB), nutrient broth (NB) or Luria broth (LB) unless otherwise specified. It’s 
recommended the broth medium to be prepared in sterile 100 mL flask and autoclaved at 
121 °C for 30 minutes before use. The prepared broth medium can be stored at 4 °C for 
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up to two weeks. 10-20 mL broth medium in sterile test tube covered by aluminum foil is 
used to culture bacteria that have been grown on the agar medium. One to two bacteria 
colonies are aseptically removed from the agar plate by sterile loop and add to the 
medium. The medium should be incubated overnight at 37 °C. After that 10-20 µL 
overnight growth is inoculate into 10-20 mL fresh broth medium and incubate at 37°C for 
5-6 hours or until specific optical density (OD600 nm) is reached. This allows the bacteria 
population to reach vegetative state during which they are most metabolically active. The 
optimal duration of incubation should be determined for each strain vial serial dilution 
(see next section).  
Frozen sample preparation  skim milk is used as medium to prepare frozen 
bacterial sample. The skim milk should be prepared fresh and stored at 4 °C for up to one 
week. Cryogenic tubes (Corning®, 1.5 mL) should be sterilized at 121 °C before used. 
After the bacteria have grown to vegetative state, the broth medium is spin down at 
10,000 rpm for 5 minutes to collect all bacterial cells. The cell pellet is re-suspend in 1 
mL skim milk in the cryogenic tube and vortex vigorously to ensure bacterial cells are 
well-mix with skim milk. The cryogenic tube is stored at -80 °C or vapor phase of liquid 
nitrogen.  
 
8.2  - Quantitation of Bacterial Cells by Serial Dilution  
Overnight cell culture is the only method to quantitatively determine the amount of 
live bacterial cells in a sample (in the unit of colony forming unit, cfu/mL). Serial 
dilution of the bacterial sample is needed before inoculate onto plate medium. The 
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procedure is following 
1. Starting with 1 mL bacterial sample, dilute the sample 10-fold each time with 9 
mL freshly prepared, sterilized, double-filtered saline aseptically until reaching 
10-6 original concentration, i.e. perform dilution six times.  
2. Transfer 0.5 mL 10-6 on agar plate with sterile pipette. 
3. Spread the bacteria evenly on the plate with sterilized glass beads. Discard the 
beads in 10% bleach afterward and incubate the agar plate at 37 °C overnight. 
4. Count the number of colonies on the agar plate after incubation.  
# of colonies on the plate x 106 (dilution factor) / 0.5 mL = cfu/mL 
 
8.3  - Special Laboratory Cultivation Guideline for Neisseria 
gonorrhoeae 
Neisseria gonorrhoeae are fastidious Gram-negative bacteria that require 
supplementary nutrient in addition to conventional bacteriological medium. In addition, 
Neisseria gonorrhoeae also needs to be grown in 5% CO2 with constant shaking.  
Material:  
Agar medium: BD® BBLtm Prepared Chocolate II Agar (GC II agar with hemoglobin 
with IsoVitaleX®) purchased from Fisher Scientific®.   
Broth Medium: Prepare Solution A and Solution B separately in clean, sterile flask. 
Autoclave Solutions A and B separately at 121 ºC for 20 minutes. Allow both solutions to 
cool to 50 ºC in water bath. Aseptically add Solution B to Solution A and mix very well. 
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Rehydrate 2.0 mL IsoVitaleX® according to package instructions and add aseptically to 
the mixture. After preparation the broth medium can be stored at 4ºC for up to one week.  
Solution A contents Amount (grams) 
Proteose Peptone #3 3.0 
Corn Starch 0.2 
Dipotassium Phosphate (K2HPO4) 0.8 
Monopotassium Phosphate (KH2PO4) 0.2 
Sodium Chloride (NaCl) 1.0 
DI water 100 mL 
Solution B contents Amount (grams) 
Dried Bovine Hemoglobin 2.0 
DI water 100 mL 
The bovine hemoglobin is soluble in water, however they aggregate after autoclave. 
Therefore the growing bacteria will bind to the protein aggregates and makes separation 
difficult. As such it’s recommended to follow the cultivation steps below.  
Preparation of stock sample of N. gonorrhoeae from lyophilized sample:  
1. In a sterile flask, aseptically transfer 20 mL broth medium. Add the lyophilized 
bacteria pellet to the broth medium. Allow rehydration for 48 hours.  
2. After 48 hours, inoculate three GCII plates with 10 uL broth medium each. Incubate 
for 20 hours with 5% CO2 at 37 ºC.  
3. Prepare skim milk storage medium according to the manufacturer instruction. 
Autoclave for 20 minutes at 121 ºC. Prepare three Corning® cryopreservation tubes 
with 1 mL sterilized skim milk.  
4. Aseptically strip off all bacteria colonies from the plate and transfer to the 
cryopreservation tube (One plate per tube) with skim milk. Vortex the 
cryopreservation tubes vigorously for about 10 seconds. Store the tubes at liquid 
nitrogen vapor phase.  
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Laboratory cultivation of N. gonorrhoeae from stock sample 
N. gonorrhoeae (FA1090) is obtained from ATCC®. The broth medium to grow 
this bacteria strain is 814 broth medium supplement with bovine hemoglobin and 
IsoVitaleX® (BD®). However, we found that the hemoglobin in the broth medium 
aggregates and precipitate out of the broth medium after sterilization. When using this 
broth medium to grow the bacteria, it’s almost impossible to completely separate the 
bacterial cells from the hemoglobin aggregation by centrifugation. To solve this problem 
we decided to grow the bacteria on the GC II agar and harvest them by stripping them off 
the plate with sterilized loop. After several rounds of trial and error we develop a reliable 
procedure to yield log-phase N. gonorrhoeae that produce robust signal on our SERS 
substrate using combination of the broth medium and the GC II agar. First the bacteria 
are grown on a GC II plate from frozen stock sample overnight at 37 °C with 5% CO2. 
Then three to four colonies from the plate is removed with sterilized loop and inoculate 
into a sterile flask containing 20 mL broth medium. The bacteria is allowed to grow in 
the broth medium with constant shaking for 20 hours at 37 °C and 5% CO2. After that, 
one loop (~ 10 µL) is used to inoculate onto a fresh GC II agar plate and incubate for 18 
hours at 37 °C and 5% CO2. The bacteria cell are harvested from the agar plate by 
stripping the colonies off the plate with sterilized loop.   
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8.4  - In vitro cultivation for non- LGV serovar Chlamydia trachomatis 
Introduction 
Chlamydia species are Gram-negative, obligate intracellular bacteria which 
require a mammalian epithelial cell for proliferation and survival. Therefore, it cannot be 
cultivated with conventional bacteriological broth medium. This property of Chlamydia 
species is the reason why laboratory cultivation for this species is expensive, difficult and 
labor-intensive. Up until 1965, Chlamydia species cultivation is done through passage in 
the yolk sack of the embryonated hen egg. Since then several mammalian epithelial cell 
lines are found eligible for Chlamydia trachomatis proliferation, making possible for 
cultivation and isolation of large quantity of Chlamydia possible. The procedure 
describes here use McCoy cell (ATCC® CRL-1696) as host cell line.  
Chlamydia trachomatis species is consisted of 15 serovars dividing into three 
different biovars. All Chlamydia trachomatis serovars are Biosafety Level 2 pathogen, 
with the exception of the LGV serovars which requires Biosafety Level 3 facilities. 
Serovars Biovars/diseases causing 
Ab, B, Ba, C Trachomatis – the leading cause of preventable blindness in 
developing countries64 
D, E, F, G, H, I, J, K Causing sexually transmitted diseases, including pelvic 
inflammatory disease, infertility, ectopic pregnancy, neonatal 
pneumoniea and neonatal conjunctivitis60,63 
L1, L2, L3 Lymphogranuloma venereum (LGV) 
 
As different serovar requires different incubation time as well as dilution ratio, it’s up to 
the researcher to determine the ideal ratio for each serovar. This protocol describes 
procedure for Chlamydia trachomatis Serovar D (ATCC® VR-885). Description for 
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cultivation of the LGV serovars will be included at the end of this section. For more 
general information, please refer to ATCC® guideline and literature [177].  
 In vitro Cultivation of Chlamydia trachomatis is consisted of three main stages: 
the growth of host cell, infection by Chlamydia, and isolation and storage of elementary 
body (EB). For Serovar D, this process takes approximately eight days, with 72-96 hours 
of infection time depends on the concentration of EB inoculated. It’s worth-noting that 
the inclusion bodies cause by Serovar D are much smaller than those by the LGV strains, 
and a much higher (some protocol reported 10:1) inoculum to host cell ratio is required to 
create a decent yield of EB. Therefore it’s up to the researcher to determine the exact 
harvest time depends on the growth and size of inclusion body.  
Material - Stage 1 
Minimal Essential Medium (MEM) supplemented with 10% fetal bovine serum (FBS), 
Dulbecco Phosphate Buffered Saline (DPBS), trypsin-EDTA, T75 cell culture flask. 
Low-speed bench-top centrifuge. Additional sterilized centrifuge tubes or micro-
centrifuge tubes 
- MEM can be purchased from various vendors such as ATCC® or Life 
Technologies®. However the FBS MUST be purchased from ATCC®, as they are 
certified to not containing any inhibitory factors for Chlamydia growth. The 
researcher also need to vigorous monitor the growth of Chlamydia to ensure the 
absence of inhibitory factors.  
- Since Chlamydia is a bacteria, Penicillin-streptomycin (Penn-Strep) or any 
antibiotic SHOULD NOT be added to the growth medium.  
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Material - Stage 2 
Dulbecco’s Minimal Essential Medium (DMEM) with 10% FBS supplement with 1 
µg/mL cycloheximide, Sucrose/phosphate/glutamate buffer (SPG) or Hass Balanced Salt 
Buffer (HBSS), low-speed bench-top centrifuge. Intermediate (x30,000g) centrifuge with 
refrigerated unit (located on EBR701 or LSEB 6th floor), 10x Diethylaminoethyl-dextran 
(DEAE-Dextran) in HBSS buffer (final concentration needed, 45 µg/mL). Platform 
rocker. Inverted microscope (10x and 25x objective), Sterilized Nalgene® centrifuge tube 
and micro-centrifugation tube, pipette tips. 
- HBSS is commercially available and can be used in exchange of SPG. The receipt 
for SPG is attached at the end of this section.  
Material - Stage 3 
Sterilized Nalgene® centrifuge tube, 50 mL centrifuge tube and 0.5 mL micro-centrifuge 
tube, ice-cold HBSS buffer, ice, 1 liter 10% bleach and 70% ethanol in spray bottle.   
Procedure 
*  Stage 1 procedure is essentially the growth and maintenance of the McCoy cell. Refer 
to Appendix 8.5  - Common tissue culture protocols 
Stage 1 - Day 1  
1. Seed one McCoy cell stock sample (usually contain ~106 – 107 cell/mL) in two T75 
flasks. Use 7 mL of DMEM with 10% FBS on each flask. Incubate the flasks at 
humidified 37 ºC incubator with 5% CO2.  
Stage 2 - Day 2 
1. Replace the medium with 7 mL fresh complete growth medium.  
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2. Check confluency under microscope, trypsinized the cell layer to prepare a frozen 
sample if necessary. Label name, date and cell count results on the container.   
Stage 3 - Day 3 
1. Check confluency. The desire coverage is 90% - 95%. Trypsinize the cell layer and 
re-seed back to the flask. 
- This ensure the cell are most viable and metabolically active during infection. 
2. Prepare for infection tomorrow. Prepare MEM with 10% FBS and 1 µg/mL 
cycloheximide. Prepare and sterilized SPG or use HBSS. Prepare 10x DEAE-dextran 
in HBSS (i.e. 450 µg/mL). Kept all reagents, medium and centrifuge tubes cold. 
Stage 2 - Day 4 
1. Final check of cell confluency and viability. Make note of anything unusual.  
2.  Warm up HBSS and 10x DEAE-dextan in 37 ºC water bath. Keep the cap away from 
the water to avoid contamination. Diluted 10x DEAE-dextran to final concentration 
(45 µg/mL) with HBSS.  
3. Remove growth medium from flask. Rinse the cell layer twice with 10 mL HBSS.  
4. Add 5 mL diluted DEAE-dextran to the cell layer. Incubate at room temperature for 
fifteen minutes.  
- Treating the cell layer with the positively-charged DEAE-dextran can neutral the 
negative charges on the cell surface, allowing EB to enter easier. As such it’s 
normal that after the treatment some cells (especially on the edges of the flask) 
fall off from the container wall.  
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5. Remove the DEAE-dextran. Rinse the cell layer with 10 mL HBSS.  
6. Remove one Chlamydia stock sample (100 µL) from the -80 ºC freezer. Quickly thaw 
at 37 ºC water bath.  
- Chlamydia EB lost viability rapidly at warm temperature. Thaw in < 1 minute.   
7. Transfer the stock sample to 7 mL DMEM/10% FBS/cycloheximide. Gently lay the 
medium over the cell layer.  
- All contaminated disposable container and pipettes must be treated with 10% 
bleach overnight before disposed in biohazard waste box. Make sure to coat all 
surfaces with bleach.  
8. Place the cell flask on the platform rocker. Rock the cell flask for three hours at room 
temperature at minimal speed.  
- To avoid contamination, cap the flask tight and seal it with parafilm. Make sure to 
cover the filter opening.  
9. Incubate the cell flask at humidified 37 ºC incubator with 5% CO2. 
Stage 2 - Day 5-7 
1. Monitor formation and size of inclusion body daily under microscope. Pay close 
attention to anything unusual (medium color, turbidity, etc). In general the harvest 
window for this serovar lies between 72-96 hours. (Insert cell image from 24 hrs, 
48 hr, 72 hrs). 
2. Preparation for harvest ( done by the night before harvest)  
- Check all necessary reagents. They must be stored in cold until use. 
- Sterilize necessary containers: pipette tips, centrifuge tubes, micro-centrifuge 
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tubes and glass beads. Kept sterilized containers sealed and cold until use. 
Stage 3 – Day 8 (harvest) 
Preparation: Pre-cool bench-top centrifuge and intermediate centrifuge (ERB) to 4 ºC. 
Obtain ice in Styrofoam box. Prepare 500 mL 10% bleach and set aside. Spray in two 50 
mL centrifuge tubes, two sterilized Nalgene® centrifuge tubes, dozen sterilized micro-
centrifuge tubes, glass beads and 50 µL pipette tips.  
* Since Chlamyida EB lose viability at room temperature without host cell, it’s 
recommended that total harvest time (exclude the centrifuge time) should be less than 10 
minutes.  All reagents and containers in contact with the EB should be cold or kept in ice 
until use, and coat with 10% bleach thoroughly and left overnight before disposal.  
1. Remove cell flask from incubator. Final check cell condition and inclusion body 
size under microscope.  
2. Transfer 10-15 glass beads to one of the 50 mL centrifuge tube.  
3. Add the beads to flask. Shake vigorously.  
- Most host cells will rupture and detached from the flask wall under the mechanical 
forces of the glass beads.  
- The presence of FBS in the medium will cause formation of large amount of foam in 
the container. Pay extreme caution not to cross-contaminate as the foam contains EB.  
4. Transfer the content in the flask to the 50 mL centrifuge tube (including the foam). 
Immediately submerge the centrifuge tube in ice.  
5. Using a new pipette each time, wash the glass beads and the container wall with 5 
mL HBSS. Add the content to the other 50 mL centrifuge tube.  
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6. Centrifuge both 50 mL centrifuge tubes at x 500g for 15 minutes at 4 ºC. Make 
sure to balance by adding HBSS.  
7. Decant the liquid to a sterile Nalgene® centrifuge tube. Careful not to disturb the 
cell debris at the bottom of the tube. Submerge the Nalgene® tube in ice in the 
Styrofoam box. Fill the other Nalgene® tube with HBSS for counterweight. 
8. Bring the Styrofoam box to ERB701.  Centrifuge at x 30,000 g for 30 minutes 
with breaks off.  
9. Carefully remove the centrifuge tube from the instrument. Note the small white 
pellet near the bottom of the tube. This is the EB/RB mixture. Submerge the tube 
in ice and brought back to the lab. 
- Since this is a shared facility which is highly prone to cross-contamination, it’s not 
recommended to open the container even under the bio-hood there.   
10. In the hood, carefully decant the liquid to 10% bleach without disturbing the 
pellet.  
11. Using a new pipette, add 1 mL ice-cold HBSS to the side opposite to the pellet. 
Gently tilt the tube several times so pellet can be washed by the HBSS.  Decant 
the HBSS and use a 50 µL pipette to remove any remaining HBSS. 
12. Depends on the size of the pellet, add 200 – 500 µL ice-cold HBSS to the tube. 
Use a 50 µL pipette to disperse the pellet. Can vortex in addition.  
13. Aliquot into 0.5 mL micro-centrifuge tubes with 100 µL each. Label date and 
name. 
14. Store the micro-centrifuge tubes in -80 ºC freezer.  
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15. Coat all containers and pipettes with 10% bleach and left overnight. Wipe down 
the hood surface with 70% ethanol.  
Stage 3 – Day 8 (re-infect) 
 If subsequent growth is required to obtain more EB, Step 7-14 can be omitted. 
Instead, at Step 5 use 5 mL ice-cold DMEM/10%FBS/cycloheximide instead of HBSS to 
wash the glass bead and the container wall and add to 50 mL centrifuge tube. Centrifuge 
at x500g for 15 minutes. Use the liquid to infect a fresh layer of McCoy cell follow the 
procedure in Stage 2 – Day 4. Note that the working volume limit for T75 flask is 15 mL.  
Procedure for cultivation of the LGV serovars 
 The cultivation of the LGV serovars is essentially the same as described above 
except two notable difference. First, pre-treatment of the host cell with DEAE-dextran is 
not needed because the infectivity of LGV serovars are much higher than the non-LGV 
ones. Cycloheximide may not be needed. Second, the incubation time for EB is much 
shorter – 28-36 hours instead of 72-96 hours. The inclusion body size is also much larger 
than the non-LGV ones.  
 
8.5  - Common tissue culture protocols 
Contrast to cultivation of vegetative bacterial cells which can happen through suspension 
in liquid broth medium, almost all mammalian cell must anchor on a suitable surface for 
proliferation. Cell suspension in liquid medium is indication of cell lysed and death. 
Therefore agitation or shaking should be avoided to prevent cells from detach from the 
cell culture container surface. It’s recommended to use tissue cell culture flask with non-
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wettable, vented filter cap instead of well plates to prevent contamination. Containers and 
workspace for tissue culture and for cultivation of vegetative bacteria must be separated. 
If not an option, the area must be thoroughly dis-infected with 70% ethanol spray or 10% 
bleach between two culture experiments.    
TISSUE CULTURE REAGENTS 
Phosphate Buffer Solution (PBS) – Can be prepared by adding appropriate number of 
PBS tablets (Sigma-Aldrich®) to appropriate volume of distilled water and sterilize by 
autoclave (121 ºC for 20 minutes) or can be purchased directly. Un-open PBS can be 
stored at room temperature until expiration specified on the package. Open PBS is 
recommended to aliquot into several Corning® medium storage bottle and stored at 4 ºC.  
Trypsin-EDTA – is recommended to purchase from Gibco® or Sigma-Aldrich instead 
prepared in the lab. Avoid repeat freeze-thaw. Aliquoted Trypsin-EDTA should be stored 
at -20 ºC until expiration date specified on the package.  
Serum – Choice of serum should be based on product sheet provided by the 
manufacturer or as guided by literature. The most common choice of serum is fetal 
bovine serum (FBS). It’s recommended FBS to be purchased from American Type Cell 
Collection (ATCC®) as the quality is vigorously and routinely checked and guaranteed 
high quality. The FBS are used directly without heat-inactivation. Other type of serum I 
had used includes heat inactivated donor equine serum (DES) and heat inactivated donor 
calf serum (DCS), both are commercially available. ATCC® also provided detailed 
instruction for heat-inactivation treatment of serum if needed.  
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Complete growth medium – The receipt for the complete growth medium should 
always refer to ATCC® product information or guided by literature. Generally complete 
growth medium for tissue culture are consisted of the following components: 
90 mL base media (DMEM, MEM, RPMI, etc, as specified by ATCC® product 
information or literature guidance). It’s best to purchase the base media from ATCC® or 
Gibco® instead of attempt to prepare on in the lab. I always choose the base media with 
high glucose and with L-glutamine.  
10% (or 10 mL) Fetal Bovine Serum (or other serum specified by ATCC® product sheet 
or literature guidance)  
Any other additional component specified by the product sheet. 
Most tissue culture guideline suggests adding 1% Penicillin-Streptomycin to 
prevent bacterial growth in the growth medium. However, under special circumstance (eg. 
cultivation of Chlamydia trachomatis) antibiotic should not be used. I found that 
antibiotic is not always necessary with strict application of aseptic techniques. It’s up to 
the individual researcher to evaluate the risk and benefit of using antibiotic for specific 
cell lines. It’s important to note that regardless adding antibiotic or not, the prepared 
complete growth medium must be stored aseptically in 4 ºC and used up or discarded 
within 14 days. Sterile Corning® medium storage bottle with air-sealed O-ring should 
always be used when preparing the complete growth medium.  
STERILIZING TECHNIQUES 
 Strict sterilization techniques must be implemented at all times especially when 
addition to antibiotic to complete growth medium is not an option (e.g. during cultivation 
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of Chlamydia trachomatis). The first rule of thumb is to treat every surface outside of the 
biosafety hood as un-sterile. The second rule of thumb is to always wear personal 
protection when performing experiment – the PPT is to protect the cells being 
contaminated. The third rule of thumb is to discard everything associated (disposable 
equipment, media, buffer solution, etc) as soon as a contamination event is discovered 
and thoroughly clean all surface that had contacted during the contamination event. The 
biosafety hood must be operated as instructed and wiped down with 70% ethanol before 
experiment starts. The UV lamp must be on at all time unless for an extended period of 
inactivity with the biosafety hood. All items enter the biosafety hood must be wiped 
down with 70% ethanol. Whenever possible, use individually wrapped, disposable 
containers and pipettes instead of glass ones. After experiment the biosafety hood must 
be wiped down with 70% ethanol.  
 Another main “hotspot” for contamination is the incubator since it’s a warm, 
humid environment all the time. Therefore, it’s recommended the incubator should be 
clean with 10% bleach regularly. The frequency of cleaning depends on the usage of the 
incubator but minimally once every months. Condensation near glass door and on top 
racks must be removed as often as possible. The water used to create the humid 
environment are placed in a stainless tray at the bottom rack. The water must be sterilized 
for three hours at 150 ºC and leave in the biosafety hood with UV lamp on overnight 
before putting into the incubator. Sodium hydroxide pellets are added to the water in the 
tray to prevent any micro-organism growth in the water while in the incubator.  
 A waste container with 10% bleach should be always available to collect any 
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discarded liquid. Never leave the waste container un-capped – micro-organisms from the 
air can fall into the waste container and starts to proliferate. By the same token never 
waive your hand over open media container even with glove on, as air turbulence can 
bring micro-organisms into the containers. Always insert sterile pipette into container 
bottom to transfer media and buffer instead of pouring off the container because the 
container edge may be contaminated especially there are liquid left from previous transfer.  
THAWING CELLS 
1. Aseptically transfer 5 mL of completed growth medium to a sterile 15 mL 
centrifuge tube.  
2. Quickly thaw the frozen vial of cells in 37 ºC water bath for 1 minutes. The 
principle is to thaw quickly so cells are not recovering in the DMSO-containing 
storage solution.  
3. Dried off water from the vial. Spray and wipe the vial with 70% ethanol.  
4. Transfer the cells/media to the 5 mL completed growth media. Gently re-suspend 
the cells.  
5. Spin down the cell at 750-1000 rpm at room temperature for 5 minutes. 
6. While centrifuging, transfer appropriate volume of complete growth medium to 
tissue culture flask. The volume  for different size container is summarized below 
Container size Working volume (mL) 
6-well plates 2 mL per well 
25 cm2 flask 5 – 10 mL 
75 cm2 flask 10 -15 mL 
225 cm2 flask 50 – 75 mL 
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7. Aspirate off supernatant.  
8. Re-suspend the cell pellet in 4 mL fresh growth media and evenly divide it into all 
tissue culture flasks containing appropriate amount of complete growth medium.  
Square-shake (north-south twice follow by west-east twice) the flask to distribute 
cell evenly the entire surface.  
9. Allow cells to grow at 37 ºC with 5% CO2 with humidity. 
10. Check confluency in 24-48 hours. Change media or split the cell if near confluent 
(want at least 80% confluent). It’s recommended to change media 24 hours prior 
to splitting to ensure highest viability.  
SPLITTING CELLS 
1. Warm up the complete growth medium, PBS buffer and trypsin-EDTA solution in 
37 ºC water bath. Spray and wipe with 70% ethanol. For cells grow in serum-free 
media, a trypsin-inhibitor solution is necessary to neutralize the enzymatic action 
of trypsin.  
2. Remove the complete growth medium from the culture flask. 
3. Rinse cell layer once with 5 mL PBS. This is important as it’s necessary to 
remove leftover proteins from the complete growth medium prior to introduction 
of trypsin. 
4. Trypsinize cells with 1-3 mL trypsin-EDTA. The volume used depends on the 
size of flask but generally should be enough to cover the entire cell layer. Do not 
over trypsinize or the cells will die. It’s recommended to monitor the process 
under inverted microscope if first time working with the cell line. Trypsin works 
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best when warmed to 37 ºC. Therefore hard to detach cells can be incubated with 
trypsin in 37 ºC to facilitate the trypsinization process.  
5. Add equal volume of serum-containing growth media or trypsin inhibitor solution 
to neutralize the trypsin. The neutralization is thought to be instantaneous.  
6. Spin down the cell at 750-1000 rpm for 5 minutes.  
7. Aspirate off the trypsin-containing media.  
8. Prepare for frozen vial or continue cultivation. Transfer desired amount to newly 
labeled tissue culture flask (NOT the old ones), label cell line name, date, passage 
number dilution factor and type of media.  
FREEZING CELLS 
 Freezing cells ensure future supply of the cell line as well as particular passage. 
However, the freezing process is considered one of the most stressful procedure to the 
cells and therefore should be carried out only during log phase when majority of the cells 
in the population is vital and metabolically active. Cell freezing procedure can also act as 
inherent selection process whereas the less-healthy cells will not be able to survive. 
Contrary to the thawing process, freezing cells should be carried out slowly and with 
gradual decrease of temperature to minimize the formation of ice crystal in the cell. Some 
delicate cell line require special freezing procedure and extra care during freezing.  
DMSO is used in all freezing procedures to reduce ice crystal formation. All frozen cells 
should be permanently stored in the vapor phase of liquid nitrogen.  
1. Prepare the following two sterile stock solutions fresh, sterile filtered and place in 
ice prior to freezing.  
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Solution A:  40% serum, 60% growth medium (DMEM, MEM, etc), 10 mM HEPES 
Solution B: 10% DMSO, 90% growth medium (DMEM, MEM, etc), 10 mM HEPES 
2. Label sterile cryogenic vials (Corning®, total volume 1.5 mL) with name of the 
cell line, passage number, cell counts and date freezing with permanent marker 
and pre-cool in ice.  One T75 cells of healthy, confluent adherent cell layer = two 
vials = one mL Solution A+ Solution B per vial. 
3. Trysinize cells. While spinning down the cells, perform cell counts with 
hemocytometer (see next section).  
4. After spinning down, remove supernatant and re-suspend cell pellet in 1 mL 
Solution A into the vial. Pipet up and down gently. 
5. Slowly add 1 mL Solution B to the vial, turning the tube to mix as Solution B is 
added, pipet up and down gently and ensure thorough mixing.  
6. Place vials at upright position in styrofoam tray and place in -80 °C for at least 24 
hours, then place in the vapor phase of liquid nitrogen for permanent storage. 
Some delicate cell lines (usually the normal cell lines and those that are hard to 
grow) may need to be placed in -20 °C for several hours prior to transfer -80 °C to 
ensure maximum recovery when thawed. 
7. Always leave one test vial to make sure the freezing was successful especially 
when first working with the cell line.   
COUNTING VIABLE CELLS WITH HEMOCYTOMETER 
1. In a clean microcentrifuge tube, combine 1:1 dilution of cells in media and 
Trypan Blue Stain (Sigma®). Quickly mixing with pipet. 
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2. Load 15-20 µL to the space between a hemocytometer and hemocytometer cover 
slip. Count numbers of unstained (viable) cells in 1 – 5x5 square field.  
 
Trypan Blue is toxic and will stain viable cells if left for long time at room 
temperature. Therefore results beyond one minutes after mixing should be discarded.  
(# viable cells)*1x104 * dilution factor = viable cell / mL 
When using 1:1 mixture, the dilution factor is 2. Sometimes when cell number is 
large (> 50 cells per counting grid) further dilution is needed to accurately determined 
the cell number.  
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Image source: http://www.ruf.rice.edu/~bioslabs/methods/microscopy/cellcounting 
 
8.6  - Receipt for Common Buffer System 
1. DEAE-dextran, 10X 
180 mg DEAE-dextran (Sigma-Aldrich®) adjust volume to 400 mL with HBSS buffer 
(450 µg/mL concentration)  
Sterilize by filtration with 0.2 micron syringe filter (Do not autoclave as the concentration 
may change due to evaporation)  
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Dilute 1:10 for pretreatment of tissue culture monolayer prior to infection (final 
concentration 45 µg/mL). The volume of DEAE-dextran used and culture condition are 
summarized below 
Size of plate or 
flask 
Cell concentration 
(cells /mL) 
DEAE-dextran 
(mL) 
Final culture 
volume (mL) 
6-well plate 4.0 x 105 2 3 
75 cm2 flask 2.0 x 106 5 8-10 
150 cm2 flask 1.0 x 107 10 40-50 
225 cm2 flask 5.0 x 108 15 75-100 
 
The 10x buffer can be stored at -20 °C for 6 months. The diluted buffer should be 
discarded after experiment.  
2. K-36 buffer, 10X 
87.1g K2HPO4 68.0g KH2PO4 74.5g KCl 8.7g NaCl 
 
Bring volume to 1L with deionized water. Adjust pH to 7.0 with 1M KOH. 
Autoclave at 121 °C for 20 minutes.  
Store up to 1 year at 4°C 
3. Sucrose-phosphate-glutamate buffer 
7.5g sucrose 0.467g Na2HPO4 • 7H2O 0.0312g NaH2PO4 0.072g L-glutamic acid 
 
Bring volume to 100 mL with deionized water. Adjust pH to 7.4 with 2M NaOH 
Autoclave at 121 °C for 20 minutes 
Store up to 1 year at 4°C. 
4. Renografin solutions, 30% 40%, 44% 54% 
Prepare the following in a biological safety cabinet to maintain sterility: 
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30, 40, 44, 54 mL Renocal-76 or Hypaque-76 (for 30%, 40%, 44% 54% solutions 
respectively  
10 mL 10X K-36 buffer (see recipe) 
Adjust volume to 100 mL with sterile, double-filtered water 
Can be stored up to 6 months at 4 °C. 
5. Dulbecco’s phosphate buffered saline (DPBS), no calcium, no magnesium  
* DPBS are commercially available through many vendors. The formulations between 
different vendors are pretty similar. List below is the formulation of DPBS from Gibco®. 
KCl, 200 mg/mL KH2PO4, 200 mg/mL NaCl, 8000 mg/mL Na2HPO4 • 7H2O, 
2160 mg/mL 
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